



2005 Fact Book

National Cancer Institute

2005 Fact Book

U.S. DEPARTMENT
OF HEALTH AND
HUMAN SERVICES
National Institutes
of Health

The information set forth in this publication is compiled and amended annually by the financial management staff of the National Cancer Institute and is intended primarily for use by members of the Institute, principal advisory groups to the Institute and others involved in the administration and management of the National Cancer Program. Questions regarding any of the information contained herein may be directed to the Financial Management Branch, National Cancer Institute, 9000 Rockville Pike, Bethesda, Maryland, 20892.

TABLE OF CONTENTS

Executive Summary	Fiscal Year 2005 Annual Report.....	iii
Organization	Director's Biography..... Former Directors of the NCI..... National Cancer Advisory Board..... Boards of Scientific Counselors and Advisors President's Cancer Panel Executive Committee Members NCI Director's Consumer Liaison Group..... Organization Charts: National Cancer Institute Office of the Director OD I: Office of Management OD II: Office of the Deputy Director OD II: Center for Strategic Scientific Initiatives OD II: Office of Education and Special Initiatives OD III: Office of Centers, Training and Resources OD IV: Center to Reduce Cancer Health Disparities OD IV: Office of Budget and Financial Management OD IV: Office of Science Planning and Assessment OD IV: Office of Communication..... Center for Cancer Research..... Division of Cancer Epidemiology and Genetics Division of Cancer Prevention..... Division of Cancer Control and Population Sciences..... Division of Cancer Treatment and Diagnosis..... Division of Cancer Biology Division of Extramural Activities.....	O-1 O-2 O-3 O-7 O-8 O-8 O-9 O-10 O-11 O-12 O-13 O-13 O-13 O-14 O-15 O-15 O-15 O-15 O-16 O-18 O-19 O-20 O-21 O-22 O-23
Cancer Statistics	Number of Deaths for the Five Leading Cancer Sites Relationship of Cancer to the Leading Causes of Death in the U.S. Estimated New Cancer Cases and Deaths..... The Cost of Cancer..... Average Years of Life Lost Per Person Dying of Cancer..... Five-Year Relative Survival Rates by Cancer Site..... Cancer Incidence Rates Cancer Mortality Rates Changes from 1992 to 2003..... Cancer Incidence Rates by Race Cancer Mortality Rates by Race The Prevalence of Cancer	C-1 C-1 C-2 C-3 C-4 C-5 C-6 C-7 C-8 C-9 C-10
Budget Data	NCI Budget Program Structure Extramural Funds NCI Obligations by Mechanism..... Division Obligations by Mechanism NIH Management Fund, Service & Supply Fund and GSA Rent... Special Sources of Funds	B-1 B-2 B-3 B-4 B-5 B-6 B-7

Extramural Programs	Funding for Various Research Areas.....	B-8
	Research Project Grants:	
	Number of Awards	E-1
	Requested, Awarded	E-2
	Awards by Activity Code	E-3
	Activity Code Descriptions	E-4
	Cancer Centers	
	By State	E-5
	Specialized Programs of Research Excellence (SPORE)	E-6
	National Research Service Awards – Pre and Post Doctoral Trainees	E-7
	Construction/Renovation Funding.....	E-8
	Grant and Contract Awards by State	E-9
	Grant and Contract Awards by Country.....	E-10
	Institutions Receiving More than \$15,000,000 in NCI Support	E-11
Historical Trends	Appropriations of the NCI	H-1
	Bypass Budget Requests	H-2
	Comparison of Bypass Requests and Appropriations of the NCI .	H-3
	Comparison of Dollars, Positions and Space.....	H-4
	Personnel Resources	H-5
	AIDS Funding History	H-6

This publication may be viewed on the World Wide Web by pointing a browser to the Financial Management Branch homepage on the National Cancer Institute's website: www.nci.nih.gov or www.cancer.gov.

Fiscal Year 2005 Annual Report

BUDGET IN REVIEW

This report provides a summary of the distribution of the Fiscal Year 2005 budget among the various National Cancer Institute (NCI) research programs and funding mechanisms, funding policies influencing grant awards, and comparisons with prior year allocations. Additional information on the NCI budget is accessible from the NCI Home Page (<http://www.cancer.gov>).

Summary

Funds available to the NCI in FY 2005 totaled over \$4.795 billion, reflecting an increase of 1.5% and \$71 million over the previous fiscal year.

Fiscal highlights from FY 2005 include:

- Of the total NCI budget, 46% of the funds were allocated for Research Project Grants.
- The total number of Research Project Grants (RPGs) funded was 5,412.
- One-fifth of the RPGs awarded were new (Type 1) or competing renewal (Type 2) awards.
- 1,292 competing RPG's were funded.
- Approximately 32% of the total NCI budget supported ongoing non-competing (Type 5) RPGs.
- R01 grants were funded to the 16th percentile.
- 265 grants – totaling nearly \$98 million – were funded as Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) awards.
- Intramural Research was just under 15% of the total NCI budget in FY 2005.
- \$532 million – over 11% of the total NCI budget – was allocated for Cancer Prevention & Control.

Distribution of the Budget by Funding Mechanism for FY 2004 and FY 2005

Summary Points

Of the \$71 million increase:

- Nearly all of the increase – or \$67 million – was allocated for the Research Grants budget mechanisms.
- \$29 million – or 39% of the increase – was provided to the Research Project Grant (RPG) category.
- Within the RPG category, competing grants and administrative supplemental grants decreased by \$58 million and the non-competing grants increased by \$87 million.
- Funds for training and career development of current and future research scientists through Research Career Awards grew by 3%; Career Education funding increased by 7%.
- The total budget for Cancer Centers, Specialized Centers (U54) and SPOREs increased by 11%.
- Specialized cancer centers include two new programs for FY2005. The Transdisciplinary Research on Energetics and Cancer (TREC) and the Nanotechnology Alliance.
- Clinical Cooperative Groups and R&D contracts decreased by 8% and 3%, respectively.
- During FY 2005, NIH and DHHS Assessments increased a total of \$19 million, including a \$11 million increase for Program Evaluation, a \$10 million increase for the Management Fund, a \$3 million reduction in other assessments including ORS Security, and a \$1 million increase for IT Assessments.

NCI Dollars by Mechanism for FY 2004 and 2005
(in thousands)

	2004	2005	Change '04-05	
			Am't	%
Research Project Grants:				
Noncompeting	\$1,513,234	\$1,600,585	\$87,351	5.8%
Admin Supplements	54,543	50,655	-3,888	-7.1%
Competing	494,003	439,870	-54,133	-11.0%
Subtotal, RPG	2,061,780	2,091,110	29,330	1.4%
SBIR/STTR	99,579	97,775	-1,804	-1.8%
Total, RPG	2,161,359	2,188,885	27,526	1.3%
Cancer Centers	245,761	255,263	9,502	3.9%
Specialized Cancer Centers (U54)	28,640	65,964	37,324	130.3%
SPOREs	134,887	133,025	-1,862	-1.4%
Total: Centers, Spec Ctrs, U54s & SPOREs	409,288	454,252	44,964	11.0%
Research Career Program	74,207	76,652	2,445	3.3%
Cancer Education	32,214	34,581	2,367	7.3%
Clinical Cooperative Groups	154,357	142,847	-11,510	-7.5%
Other Grants	54,138	54,891	753	1.4%
Subtotal, Other	314,916	308,971	-5,945	-1.9%
Total, Research Grants	2,885,563	2,952,108	66,545	2.3%
National Research Service Awards	66,264	67,299	1,035	1.6%
R&D Contracts	361,569	351,056	-10,513	-2.9%
Intramural Research	708,939	711,009	2,070	0.3%
Research Management & Support	171,578	173,702	2,124	1.2%
Cancer Prevention & Control	529,980	531,634	1,654	0.3%
Construction	0	0	0	0.0%
Buildings and Facilities	0	7,936	7,936	
Total, NCI	4,723,893 *	4,794,744 *	70,851	1.5%
AIDS research included above	[\$263,442]	[\$265,907]	[\$2,465]	0.9%

* Does not include \$3.5 million in FY2004 and \$2.9 million in FY2005 obligated by the NCI from funds collected thru the sale of the Breast Stamp by the U.S. Postal Service.


Percent Share of Total NCI Dollars

Summary Points

- The mechanism shares of the total budget have remained relatively stable from FY 2001 to FY 2005.
- Intramural Research has dropped to under 15% of total NCI dollars.

Percent Share of Total NCI Dollars

	2001	2002	2003	2004	2005
Research Project Grants	45.2%	45.3%	44.8%	45.8%	45.6%
Cancer Centers	5.1%	5.0%	5.1%	5.2%	5.3%
Specialized Centers	0.3%	0.4%	0.4%	0.6%	1.4%
SPOREs	2.0%	2.3%	2.7%	2.9%	2.8%
Clinical Cooperative Groups	4.1%	3.9%	3.5%	3.3%	3.0%
Intramural Research	15.1%	15.3%	15.1%	15.0%	14.8%
R&D Contracts	7.6%	7.1%	8.1%	7.7%	7.3%
Cancer Prevention & Control	12.2%	12.0%	11.6%	11.2%	11.1%
Other Mechanisms	8.4%	8.7%	8.6%	8.3%	8.7%



Funding Trends

Summary Points

- The NCI budget has increased by \$1.04 billion – or 28% – since FY 2001. All mechanisms, except for Research Project Grants, Intramural Research, Clinical Cooperative Groups, and Cancer Prevention & Control have experienced percentage increases greater than the total NCI growth since FY 2001.

Historical Funding Trends (Dollars in Millions)

	2001	2002	2003	2004	2005
Total NCI	\$3,753.7	\$4,176.7	\$4,592.3	\$4,723.9	\$4,794.8
Research Project Grants	1,696.6	1,893.2	2,058.7	2,161.4	2,188.9
Intramural Research	567.3	637.6	693.1	708.9	711.0
Cancer Centers	192.1	208.0	235.8	245.7	255.3
Specialized Centers	10.7	16.8	19.2	14.2	66.0
SPOREs	76.8	94.9	123.1	149.4	133.0
Clinical Cooperative Groups	154.3	163.8	158.7	154.3	142.8
Cancer Prevention & Control	459.5	501.2	533.2	530.0	531.6
R&D Contracts	284.0	298.2	370.8	361.6	351.1
Other Mechanisms	312.3	363.0	399.7	398.4	415.1

% Growth by Mechanism

	2001 to 2002	2002 to 2003	2003 to 2004	2004 to 2005	2001 to 2005
Total NCI	11.3%	10.0%	2.9%	1.5%	27.7%
Research Project Grants	11.6%	8.7%	5.0%	1.4%	29.0%
Intramural Research	12.4%	8.7%	2.3%	0.3%	25.3%
Cancer Centers	8.3%	13.4%	4.2%	3.9%	32.9%
Specialized Centers	57.0%	13.7%	-26.0%	365.0%	516.8%
SPOREs	23.4%	29.9%	9.5%	-1.4%	73.2%
Clinical Cooperative Groups	6.2%	-3.1%	-2.7%	-7.5%	-7.5%
Cancer Prevention & Control	9.1%	6.4%	-0.6%	0.3%	15.7%
R&D Contracts	5.0%	24.3%	-2.5%	-2.9%	23.6%
Other Mechanisms	16.2%	10.1%	-0.4%	2.2%	32.9%

Research Project Grants

Summary Points

- 89% of competing dollars supported grants awarded within the established payline; 11% supported grants as an exception to the payline.
- RFA funds, which increased from the FY 2004 dollar level, accounted for 10% of FY 2005 competing dollars.
- Research Project Grant applications submitted to NCI increased by approximately 3%.
- 1,292 competing RPG's were funded.

Research Project Grants (Dollars in Thousands)

	2004*		2005**	
	No.	Amount	No.	Amount
Total funding for RPGs	5,467	\$2,161,359	5,412	\$2,188,885
SBIR/STTR	397	\$99,579	265	\$97,775
Funding for RPGs without SBIR/STTR Program	5,070	\$2,061,780	5,147	\$2,091,110
Continuation or noncompeting grants funded	3,578	\$1,454,513	3,855	\$1,651,239
Competing grants funded	1,492	\$494,003	1,292	\$439,871
Administrative Supplements		\$54,543	292	\$50,655
Partial assessment for DHHS Program Evaluation		\$58,721		\$58,721
Funds set aside within competing dollars for:				
Grants within Paylines:	1,375	\$448,654	1,154	\$392,692
Traditional R01	886	\$290,361	704	\$226,797
Program Projects (P01)	33	\$52,049	38	\$65,273
RFA Grants	67	\$41,848	92	\$44,568
Share of competing grant funds		8.47%		10.13%
Exception Grants	118	\$45,349	138	\$47,179
Share of competing grant funds		9.18%		10.73%
Competing Application Requests	6,148	\$2,279,782	6,325	\$2,489,515
Funding Success Rate	24.30%		20.40%	
Percentile funding for R01 grants	20th		16th	
Average Cost-Competing		\$331		\$340
Average Reduction from recommended/requested levels		-15%		-22%


*Does not include \$3.5 million received by the NCI from the US Postal Service's sale of the Breast Cancer Stamp.

**Does not include \$2.9 million received by the NCI from the US Postal Service's sale of the Breast Cancer Stamp.

Grant Funding Paylines

RPG Mechanisms:	2004	2005	
R01 Traditional Grants	20th	16th	percentile
P01 Program Projects	N/A*	N/A*	priority score
R03 Small Grants	225	210	priority score
R21 Exploratory Phase I	166	175	priority score
R33 Exploratory Phase II	155	160	priority score
R41/R42 STTR	232	185	priority score
R43/R44 SBIR	220/210	190	priority score

* Formal paylines for P01 grants are determined by the Executive Committee




**National Cancer Institute
Extramural vs. Inhouse Funding**
(\$'s in millions)

Extramural						
Mechanism	2001	2002	2003	2004	2005	01-05% chg.
Research Project Grants	\$1,696.60	\$1,893.20	\$2,058.70	\$2,161.40	\$2,188.90	29.0%
Cancer Centers	192.1	208	235.8	245.7	255.3	32.9%
Specialized Centers	10.7	16.8	19.1	14.1	66	516.8%
SPOREs	76.8	94.8	123.1	134.8	133	73.2%
Other Research Grants	269.2	304.1	320.3	314.9	309	14.8%
NRSA	57.9	63.7	65.9	66.2	67.3	16.2%
R&D Contracts	284	298.2	370.8	361.6	351.1	23.6%
Cancer Control Grants	183.7	208.2	221.6	220	232	26.3%
Cancer Control Contracts	126.1	135.9	160	153	145.8	15.6%
Construction	3	5	5	0	0	-100.0%
Buildings & Facilities	0	0	0	0	7.9	0%
Total Extramural Funds	2,900.10	3,227.90	3,580.30	3,671.70	3,756.30	590.9%

Inhouse						
Mechanism	2001	2002	2003	2004	2005	01-05% chg.
Intramural Research	\$567.30	\$637.60	\$693.10	\$708.90	\$711.00	25.3%
RMS	136.5	154	167.3	171.6	173.7	27.3%
Control Inhouse	149.7	157.1	151.5	157	154	2.9%
Total Inhouse Funds	853.5	948.7	1,011.90	1,037.50	1,038.70	21.7%

Total NCI	3,753.60	4,176.60	4,592.20	4,709.20	4,795.00	27.7%
------------------	-----------------	-----------------	-----------------	-----------------	-----------------	--------------



Research Career Awards – “K” Program


Summary Points

- The Research Career Award mechanism grew by 3% in FY 2005.
- The number of Research Career Awards increased by 37 in FY 2005 from FY 2004.
- NCI’s funding in FY 2005 for the K30 Institutional Curriculum Awards, which are administered by the National Heart, Lung, and Blood Institute, was \$1.1 million.

(Dollars in Thousands)

	2004		2005	
	No.	Amount	No.	Amount
K01 Temin Awards	72	\$10,485	82	\$11,897
K01 Minority Mentored Career Development Award	41	5,285	45	5,837
Subtotal, K01s	113	15,770	127	17,734
K05 Research Scientist Award	19	2,396	20	2,554
K07 Preventive Oncology	88	11,393	110	13,529
K08 Clinical Investigator	131	17,243	141	17,841
K12 Institutional Clinical Oncology Research	17	8,791	13	7,436
K22 Transition Career Development	35	5,333	35	5,344
K23 Patient-Oriented Career	61	7,911	60	7,533
K24 Patient-Oriented Career -- Mid Career Mentored Quantitative Research Career Development	25	3,061	16	2,306
K25 Award	5	712	9	1,227
	494	72,610	531	75,505
K30 Institutional Curriculum Awards -- Administered by NHLBI	0	1,597	0	1,147
Total Research Career Program	494	74,207	531	76,652

National Cancer Institute
FY 2005
% of Total Research Career Award Funds



Research Dollars by Various Cancers

Summary Points

- Funding for various cancers listed below may overlap
- Funding for cancers listed below do not represent the entire NCI budget

Research Dollars by Various Cancers
(Dollars in Millions)

	2001	2002	2003	2004	2005
Total NCI	\$3,753.70	\$4,176.70	\$4,592.30	\$4,723.90	\$4,794.70
AIDS	237.8	254.4	263.4	267	265.9
Brain & Central Nervous System	80.7	95.2	111.5	132.3	107.2
Breast Cancer	475.2	522.6	548.7	566.2	560.1
Cervical Cancer	72.6	67.6	79	79	81.7
Clinical Trials	648.6	702.1	799.5	800	781.8
Colorectal Cancer	207.4	245	261.6	262	253.1
Head and Neck	50	58.9	77.7	88.2	89.5
Hodgkin's Disease	10.2	11.8	16.5	17.4	17.2
Leukemia	154	177.2	200.9	214.7	220.6
Liver Cancer	54.5	62.5	63.7	63	60.5
Lung Cancer	206.5	237.5	273.5	276.5	266.1
Melanoma	71.8	82.3	90.7	94.9	102.9
Multiple Myeloma	19.7	20.8	26.3	23.9	28.2
Non Hodgkin's Lymphoma	79.5	85.6	95.2	99.6	107
Ovarian Cancer	76.9	93.5	99.4	99.5	97.7
Pancreatic Cancer	21.8	33.1	42.3	52.7	66.7
Prostate Cancer	258	278.4	305.2	308.5	309
Stomach Cancer	9	11.4	13.4	11.6	11
Uterine Cancer	18.8	23.1	25.5	27	31.1

Organization

Cancer Statistics

Budget Data

Extramural Programs

Historical Trends

National Cancer Institute

Director's Biography

Andrew C. von Eschenbach, M.D.

Andrew C. von Eschenbach, M.D. became the 12th Director of the National Cancer Institute in January 2002. In September 2005, he was also appointed as the Acting Commissioner of the Food and Drug Administration and currently holds both positions. He is a nationally recognized urologic surgeon who formerly directed the Genitourinary Cancer Center and the Prostate Cancer Research Program at The University of Texas M.D. Anderson Cancer Center in Houston, Texas. He also served as special assistant for external affairs to M.D. Anderson's president and held the Roy M. and Phyllis Gough Huffington Clinical Research Distinguished Chair in Urologic Oncology.

A native of Philadelphia, Dr. von Eschenbach received his medical degree from Georgetown University Medical School in 1967. He completed residencies in general surgery and urology at Pennsylvania Hospital in Philadelphia, then was an instructor in urology at the University of Pennsylvania School of Medicine. He served as a Lieutenant Commander in the U.S. Navy Medical Corps.

In 1976, Dr. von Eschenbach went to M.D. Anderson Cancer Center for a fellowship in urologic oncology and was invited to join the faculty the following year. From 1983 to 1996, he was Chairman of the Department of Urology and, since 1985, has also been a Consulting Professor in the Department of Cancer Biology.

In 1996, Dr. von Eschenbach was named the founding director of M.D. Anderson's Prostate Cancer Research Program, comprised of over 60 scientists and clinicians collaborating on integrated translational research in the biology, treatment, epidemiology and prevention of the disease. From 1997 to 1999, he also served as Vice President for Academic Affairs and then as Executive Vice President and Chief Academic Officer, leading a faculty of almost 1,000 cancer researchers and clinicians.

He was a founding member of C-Change and, prior to his accepting the position as NCI Director, he was President-elect of the American Cancer Society. Dr. von Eschenbach has contributed more than 200 articles, books and chapters to the scientific literature.

Former Directors of the National Cancer Institute

Richard D. Klausner, M.D.

August 1995 – September 2001

Dr. Klausner was appointed as the Director of the National Cancer Institute (NCI) on August 1, 1995. From 1984 until 1997 he was Chief of the Cell Biology and Metabolism Branch of the National Institute of Child Health & Human Development. Dr. Klausner is well known for his contributions to multiple aspects of cell and molecular biology. Dr. Klausner's research has illuminated the genetics and biochemistry of metals as essential but toxic nutrients for virtually all forms of life, has illuminated the pathways by which molecules traffic and speak to each other within the cell, and has described novel mechanisms by which tumor suppressor genes function.

Samuel Broder, M.D.

December 1988 – March 1995

Dr. Broder joined NCI in 1972 as a Clinical Associate in the Metabolism Branch. In 1981, he became Associate Director for NCI's Clinical Oncology Program. In 1985 he led the laboratory team that discovered the therapeutic effects of AZT and other drugs now approved for the treatment of AIDS including DDI and DDC.

Vincent T. DeVita, Jr., M.D.

January 1980 – June 1980 (Acting)
July 1980 – August 1988

Dr. DeVita joined NCI in 1963 as a Clinical Associate in the Laboratory of Chemical Pharmacology. He served NCI as head of the Solid Tumor Service, Chief of the Medicine Branch, Director of the Division of Cancer Treatment and Clinical Director prior to his appointment as Director of NCI.

Arthur Canfield Upton, M.D.

July 1977 – December 1979

Prior to his tenure as NCI Director, Dr. Upton served as Dean of the School of Basic Health Sciences at the State University of New York at Stony Brook.

Frank Joseph Rauscher, Jr., Ph.D.

May 1972 – October 1976

Dr. Rauscher served as Scientific Director for Etiology, NCI, prior to his appointment as Director of NCI in 1972.

Carl Gwin Baker, M.D.

November 1969 – July 1970 (Acting)
July 1970 – April 1972

During his tenure with PHS, Dr. Baker served as Scientific Director for Etiology, NCI, and as Acting Director of NCI prior to his appointment as Director in July 1970.

Kenneth Milo Endicott, M.D.

July 1960 – November 1969

Dr. Endicott served as Chief of the Cancer Chemotherapy National Service Center, PHS, and as Associate Director, NIH, prior to being appointed Director of NCI in July 1960.

John Roderick Heller, M.D.

May 1948 – June 1960

Dr. Heller joined PHS in 1934 and became Chief of the Venereal Disease Division prior to his appointment as Director of NCI in 1948.

Leonard Andrew Scheele, M.D.

July 1947 – April 1948

Dr. Scheele served in various capacities during his tenure with PHS prior to his appointment as Assistant Chief and, subsequently, Director of NCI in July 1947.

Roscoe Roy Spencer, M.D.

August 1943 – July 1947

Dr. Spencer became NCI's first Assistant Chief and, subsequently, was appointed Director of the Institute in 1943.

Carl Voegtlin, Ph.D.

January 1938 – July 1943

Dr. Voegtlin served as Professor of Pharmacology and Chief of the Division of Pharmacy at the Hygienic Laboratory prior to becoming the first Director of NCI in 1938.

National Cancer Advisory Board

Membership and Term

2010 Acting Chairperson

Daniel D. Von Hoff, M.D., F.A.C.P

Translational Genomics Research Institute
Phoenix, AZ 85004

2006 Eric S. Lander, Ph.D.

The Broad Institute of MIT and Harvard
MIT and Harvard Medical School
The Whitehead Institute for Biomedical Research
Cambridge, MA 02141

2006 Samir Abu-Ghazaleh, M.D.

Avera Cancer Institute
Sioux Falls, SD 57105

2010 Diana M. Lopez, Ph.D.

Department of Microbiology & Immunology
University of Miami School of Medicine
Miami, FL 33136

2006 James O. Armitage, M.D.

College of Medicine
University of Nebraska Medical Center
Omaha, NE 68198

2006 Arthur W. Nienhuis, M.D.

St. Jude Children's Research Hospital
Memphis, TN 38101

2008 Moon Shao-Chuang Chen, Jr., Ph.D., M.P.H.

University of California
Davis Cancer Center
Sacramento, CA 95817

2008 Ms. Marlys Popma

IHS Consulting
Colfax, IA 50054

2008 Kenneth H. Cowan, M.D., Ph.D.

University of Nebraska Medical Center
Eppley Institute for Cancer Research
Omaha, NE 68198

2008 Franklyn G. Prendergast, M.D., Ph.D.

Mayo Clinic Cancer Center
Mayo Foundation
Rochester, MN 55905

2008 Jean B. deKernion, M.D.

Department of Urology
UCLA School of Medicine
Los Angeles, CA 90095

2010 Carolyn D. Runowicz, M.D.

The Carol and Ray Neag Comprehensive
Cancer Center
University of Connecticut Health Center
Farmington, CT 06030

2006 Ralph S. Freedman, M.B.B.Ch., Ph.D.

Department of Gynecologic Oncology
University of Texas
Houston, TX 77030

2008 Lydia G. Ryan, M.S.N., P.N.P.

Children's Healthcare of Atlanta
AFLAC Cancer Center
Atlanta, GA 30322

2006 James H. French, M.D.

The Center for Plastic Surgery
Annandale, VA 22003

2010 Kathryn Giusti, M.B.A.

Multiple Myeloma Research Foundation, Inc.
New Canann, CT 06840

Executive Secretary

Paulette S. Gray, Ph.D.

2010 David H. Koch

Koch Industries
New York, NY 10021

Committee Management Officer

Ms. Claire L. Harris

National Cancer Advisory Board (Continued)

Ex Officio Members

The Honorable Elaine Chao, M.B.A.

Secretary of Labor
Washington, DC 20210

Andrew C. von Eschenbach, M.D.

Acting Commissioner
Food and Drug Administration
Rockville, MD 20857

John Howard, M.D., M.P.H., J.D., LL.M.

Director
National Institute for Occupational Safety and
Health (NIOSH)
Washington, DC 20857

Mr. Stephen L. Johnson

Administrator
Environmental Protection Agency
Washington, DC

The Honorable Michael O. Leavitt

Secretary
Department of Health and Human Services
Washington, DC 20201

John H. Marburger, III

Science Advisor to the President
Director
Office of Science and Technology Policy
Executive Office of the President
Washington, DC 20502

Ari Patrinos, Ph.D.

Associate Director
Office of Biological and Environmental Research
U.S. Department of Energy
Washington, DC 20585

The Honorable Dr. Jonathan Perlin

Under Secretary for Health
Veterans Health Administration
Department of Veterans Affairs
Washington, DC 20420

David A. Schwartz, M.D.

Director
National Institute of Environmental Health Sciences
National Institutes of Health
Research Triangle Park, NC 27709

Mr. Hal Stratton

Chairman
Consumer Product Safety Commission
Bethesda, MD 20814

The Honorable Dr. William Windwerder, Jr.

Assistant Secretary of Defense for Health Affairs
Washington, DC 20301-1200

Elias A. Zerhouni, M.D.

Director
National Institutes of Health
Bethesda, MD 20892

National Cancer Advisory Board (Continued)

Alternates to Ex Officio Members

Michael A. Babich, Ph.D.
Directorate for Health Sciences
U.S. Consumer Product Safety Commission
Bethesda, MD 20814
(Mr. Hal Stratton - CPSC)

Louisa Chapman, M.D.
Assistant Director for Life Sciences
Office of Science and Technology Policy
Executive Office of the President
Washington, DC 20502
(John H. Marburger III, Ph.D.-OSTP)

Allen Dearry, Ph.D.
Associate Director for Research
Coordination
Division of Intramural Research
National Institute of Environmental Health
Sciences
National Institutes of Health
Research Triangle Park, NC 27709
(David A. Schwartz, M.D., - NIEHS)

Raynard Kington, M.D., Ph.D.
Deputy Director
National Institutes of Health
Bethesda, MD 20892
(Elias A. Zerhouni, M.D., - NIH)

Peter Kirchner, M.D.
Program Manager
Office of Biological & Environmental Research
Division of Medical Science
U.S. Department of Energy
Germantown, MD 20874-1290
(Ari Patrinos, Ph.D. - DOE)

T. G. Patel, M.D., M.A.C.P.
Captain MC USN (Retired)
Program Chief
Veterans Health Administration
Department of Veterans' Affairs
Washington, DC 20420
(The Honorable Dr. Jonathan B. Perlin - VA)

Richard Pazdur, M.D.
Division Director
Division of Oncology Drugs
Food and Drug Administration
Rockville, MD 20857
(Andrew C. von Eschenbach, M.D. - FDA)

John F. Potter, M.D.
Director
United States Military Cancer Institute
Walter Reed Army Medical Center
Washington D.C. 20307
(The Honorable Dr. William Winkwerder, Jr. - DOD)

R. Julian Preston, Ph.D.
Director
Environmental Carcinogenesis Division
U.S. Environmental Protection Agency
Research Triangle Park, NC 27703
(Mr. Stephen L. Johnson - EPA)

Anita L. Schill, Ph.D., M.P.H., M.A., R.N., COHN-S
Senior Scientist
Office of the Director
National Institute for Occupational Safety
and Health
Washington, DC 20201
(John Howard, M.D., M.P.H., J.D., LL.M. - NIOSH)

Donald J. Wright, M.D. MPH
Director
Office of Occupational Medicine
Department of Labor, OSHA
Washington, DC 20210
(The Honorable Elaine Chao - DOL)

Note: Bold print represents Ex Officio Members

National Cancer Advisory Board (Continued)

NCAB Subcommittee Assignments

Subcommittee on Activities and Agenda

Dr. Moon Shao-Chuang Chen, Jr.
Dr. Jean B. deKernion
Dr. Ralph S. Freedman
Ms. Marlys Popma
Dr. R. Julian Preston, EPA
Ms. Lydia Ryan
Dr. Donald Wright, DOL
EXECUTIVE SECRETARY: Dr. Cedric Long
(301) 496-9138

Subcommittee on Cancer Centers

Dr. Arthur W. Nienhuis - Chair
Dr. Samir Abu-Ghazaleh
Dr. Kenneth Cowan
Dr. Allen Dearry, NIEHS
Mr. David Koch
Dr. Carolyn Runowicz
EXECUTIVE SECRETARY: Dr. Ernie Hawk
(301) 594-2684

Subcommittee on Clinical Investigations

Dr. Jean B. deKernion - Chair
Dr. James Armitage
Dr. Ralph S. Freedman
Ms. Kathryn Giusti
Mr. David Koch
Dr. Richard Pazdur, FDA
Dr. John Potter, DOD
Dr. Daniel Von Hoff
EXECUTIVE SECRETARY: Dr. James Doroshow
(301) 496-4291

Subcommittee on Planning and Budget

Dr. Franklyn Prendergast - Chair
Dr. Moon Shao-Chuang Chen, Jr.
Dr. Eric Lander
Dr. Diana Lopez
Ms. Marlys Popma
EXECUTIVE SECRETARY: Ms. Cherie Nichols
(301) 496-5515

Subcommittee on Special Actions

Dr. Ralph Freedman - Chair
Committee of the Whole
EXECUTIVE SECRETARY: Dr. Paulette Gray
(301) 496-5147

Ad hoc Subcommittee on Communications

Ms. Lydia Ryan - Chair
Dr. Samir Abu-Ghazaleh
Dr. Michael Babich, CPSC
Dr. Moon Shao-Chuang Chen, Jr.
Dr. Allen Dearry, NIEHS
Ms. Kathryn Giusti
Dr. Diana Lopez
Ms. Marlys Popma
Dr. Anita Schill, NIOSH
EXECUTIVE SECRETARY: Ms. Nelvis Castro
(301) 435-7778

Ad hoc Subcommittee on Confidentiality of Patient Data

Dr. Kenneth Cowan - Chair
Dr. James Armitage
Dr. Ralph S. Freedman
Dr. Peter Kirchner, DOE
Dr. T. G. Patel, VA
Dr. Carolyn Runowicz
Ms. Lydia Ryan
EXECUTIVE SECRETARY: Dr. Carolyn Compton
(301) 496-1550

Ad hoc Subcommittee on Biomedical Technology

Dr. Eric Lander - Chair
Dr. Ralph Freedman
Ms. Kathryn Giusti
Mr. David Koch
Dr. Daniel Von Hoff
EXECUTIVE SECRETARY: Ms. Kathleen Schlom
(301) 435-5709

Board of Scientific Counselors Intramural Programs

Clinical Sciences and Epidemiology

Appointees	Expiration of Appointment	Appointees	Expiration of Appointment
Chair - Margaret Tempero, M.D.		2006	
Leslie Bernstein, Ph.D.	2006	Susan Mayne, Ph.D.	2009
Martin Blaser, M.D.	2010	Daniel Medina, Ph.D.	2006
David Carbone, M.D., Ph.D.	2010	Monica Morrow, M.D.	2010
Esteban Celis, M.D., Ph.D.	2008	Andrew Olshan, Ph.D.	2009
Leland Chung, Ph.D.	2008	Timothy Rebbeck, Ph.D.	2009
Scott Davis, Ph.D.	2010	Eric Rowinsky, M.D.	2008
Barbara Gilcrest, M.D.	2009	Charles Sawyers, M.D.	2009
Stanley Hamilton, M.D.	2006	David Scadden, M.D.	2007
Richard Hoppe, M.D.	2010	Steven Self, Ph.D.	2006
Elizabeth Jaffee, M.D.	2010	Paul Sondel, M.D., Ph.D.	2009
Bruce Korf, M.D., Ph.D.	2008	Ann Thor, M.D.	2010
Theodore Lawrence, M.D., Ph.D.	2009		
Susan Leigh, RN	2008		
Maria Martinez, Ph.D.	2010	Executive Secretary - Brian Wojcik, Ph.D.	

Basic Sciences

Chair - Thea Dorothy Tlsty, Ph.D.		2006	
Stephen Benkovic, Ph.D.	2008	Leona Samson, Ph.D.	2010
Christine Biron, Ph.D.	2010	Robert Siliciano, M.D., Ph.D.	2009
Olivera Finn, Ph.D.	2010	Harinder Singh, Ph.D.	2007
Sankar Ghosh, Ph.D.	2006	Ronald Swanstrom, Ph.D.	2006
Michael Gould, Ph.D.	2009	Joseph Testa, Ph.D.	2010
James Haber, Ph.D.	2010	Jeffrey Trent, Ph.D.	2009
Katherine Jones, Ph.D.	2008	Paul Ts'o, Ph.D.	2010
Michael Karin, Ph.D.	2010	Cheryl Lyn Walker, Ph.D.	2006
Laimonis Laimins, Ph.D.	2009	Teresa Wang, Ph.D.	2008
Dan Littman, M.D., Ph.D.	2007	Jerry Workman, Ph.D.	2009
Guillermina Lozano, Ph.D.	2007		
Frank Rauscher, Ph.D.	2010		
Martine Roussel, Ph.D.	2008	Executive Secretary - Florence E. Farber, Ph.D.	

Board of Scientific Advisors Extramural Programs

Chair - Robert C. Young		2007	
David S. Alberts, M.D.	2006	Kenneth W. Kinzler, Ph.D.	2006
Hoda A. Anton-Culver, Ph.D.	2006	Michael P. Link, M.D.	2007
Kirby I. Bland, M.D.	2009	Christopher J. Logothetis, M.D.	2009
Esther H. Chang, Ph.D.	2006	Lynn M. Matrisian, Ph.D.	2007
Susan J. Curry, Ph.D.	2010	Kathleen H. Mooney, Ph.D., F.A.A.N., R.N.	2010
William S. Dalton, M.D., Ph.D.	2010	Edith A. Perez, M.D.	2009
Raymond N. Dubois, M.D., Ph.D.	2007	John D. Potter, M.D., Ph.D.	2009
H. Shelton Earp III, M.D.	2007	Mack Roach III, M.D.	2007
Kathleen M. Foley, M.D.	2009	Richard L. Schilsky, M.D.	2006
Sanjiv S. Gambhir, M.D., Ph.D.	2009	Ellen V. Sigal, Ph.D.	2009
Patricia A. Ganz, M.D.	2007	Margaret R. Spitz, M.D., M.P.H.	2007
Joe W. Gray, Ph.D.	2009	Robert Tjian, Ph.D.	2010
William N. Hait, M.D., Ph.D.	2008	Jane C. Weeks, M.D.	2009
James R. Heath, Ph.D.	2010		
Mary J. Hendrix, Ph.D.	2009		
Leroy E. Hood, Ph.D., M.D.	2009		
Susan B. Horwitz, Ph.D.	2006		
Hedvig Hricak, M.D., Ph.D.	2007	Executive Secretary - Paulette S. Gray, Ph.D.	
Eric Hunter, Ph.D.	2007		
Paula K. Kim	2007		

President's Cancer Panel

LaSalle D. Leffall, Jr. M.D., F.A.C.S. 2007

Chairman
Charles R. Drew Professor of Surgery
Howard University Hospital
2041 Georgia Avenue, NW
Suite 4000
Washington, DC 20060

Margaret Kripke, Ph.D. 2006

Executive Vice President/Chief Academics Officer
University of Texas
M.D. Anderson Cancer Center
Unit 113
1515 Holcombe Boulevard
Houston, TX 77030

Lance E. Armstrong 2008

Founder, Lance Armstrong Foundation
2901 Bee Caves Road
Suite L
Austin, TX 78746

Abby B. Sandler, Ph.D.

Executive Secretary

Executive Committee Members

Andrew C. von Eschenbach, M.D.

Director

Paulette Gray, Ph.D.

Director, Division of Extramural Activities

Anna D. Barker, Ph.D.

Deputy Director, Advanced Technologies and
Strategic Partnerships

Peter Greenwald, M.D., Dr.Ph

Director, Division of Cancer Prevention

Ken Buetow, Ph.D.

Director, NCI Center for Bioinformatics

John Hartinger

Associate Director, Office of Budget and Financial Management

Nelvis Castro

Acting Director, Office of Communications

Ernest T. Hawk, M.D., M.P.H.

Director, Office of Centers, Training, & Resources

Mark Clanton, M.D., M.P.H.

Deputy Director, Cancer Care Delivery Systems

John E. Niederhuber, M.D.

Chief Operating Officer
Deputy Director, Translational and Clinical Sciences

Robert Croyle, Ph.D.

Director, Division of Cancer Control and
Population Sciences

Alan S. Rabson, M.D.

Deputy Director

James Doroshow, M.D.

Director, Division of Cancer Treatment
and Diagnosis

Sanya Springfield, Ph.D.

Acting Director, Center to Reduce
Cancer Health Disparities

Greg Downing, D.O., Ph.D.

Director, Office of Technology and Industrial Relations

Dinah Singer, Ph.D.

Director, Division of Cancer Biology

Joseph Fraumeni, M.D.

Director, Division of Cancer Epidemiology and
Genetics

Robert Wiltout, Ph.D.

Director, Center for Cancer Research

Sandy Koeneman, M.S., M.P.A.


Executive Secretary


NCI Director's Consumer Liaison Group

Mr. Doug Ulman, Chair Lance Armstrong Foundation	2008	Dr. Sylvia Ramos People Living Through Cancer/Intercultural Cancer Council	2006
Ms. Margaret L. Anthony Yul Brynner Head and Neck Foundation	2006	Mr. Eric Rosenthal EvocaTalk® Reports	2006
Ms. Vernal H. Branch Virginia Breast Cancer Foundation/ National Breast Cancer Coalition	2007	Ms. Mary Jackson Scroggins Ovarian Cancer National Alliance	2007
Mr. William Bro Kidney Cancer Association	2008	Ms. Sue Sumpter Leukemia & Lymphoma Society/Candlelighters Childhood Cancer Foundation	2007
Ms. Lourie Campos Community Health Partnership	2008	Dr. Marisa Weiss breastcancer.org	2007
Ms. Nancy Davenport-Ennis Patient Advocate Foundation	2008	Ms. Celeste Whitewolf Native People's Circle of Hope	2006
Ms. Bobbi de Córdoba Hanks Bosom Buddies/Women's Center of Jacksonville	2006	Col. (Ret.) James Williams Pennsylvania Prostate Cancer Coalition	2008
Dr. Beverly Laird American Cancer Society/Komen Breast Cancer Foundation	2007		


Ms. Brooke Hamilton, Acting Executive Secretary
Director's Consumer Liaison Group
Office of Liaison Activities
National Cancer Institute
6116 Executive Boulevard, Suite 220
Bethesda, MD 20892


National Cancer Institute







Office of Management
 Deputy Director
 Mr. Thomas Hooven
 301-435-2455









**Center for Cancer Research
Office of the Director**
Director
Dr. Robert Wiltrott
301-496-4345
Acting Scientific Director for Clinical Sciences
Dr. Lee Helman
301-496-4257
Deputy Directors
Dr. Richard Alexander Dr. Stuart Yuspa
Dr. Jeffrey Strathern Dr. Douglas Lowy
301-496-4346

Laboratory of Cancer Prevention
Chief
Dr. Nancy Colburn
301-496-6874

Laboratory of Mammary Biology &
Tumorigenesis
Chief
Dr. Barbara Vonderhaar
301-594-9940

Laboratory of Genetics
Chief
Dr. Beverly Mock
301-496-1734

Laboratory of Tumor Immunology
and Biology
Chief
Dr. Jeffrey Schlom
301-496-4343

Laboratory of Experimental
Carcinogenesis
Chief
Dr. Snorri Thorgeirsson
301-496-1935

Laboratory of Biochemistry
Chief
Dr. Michael Lichten
301-496-5957

Laboratory of Cellular and Molecular
Biology
Chief
Dr. Larry Samelson
301-496-9683

Laboratory of Cellular
Carcinogenesis and Tumor
Promotion
Chief
Dr. Stuart Yuspa
301-496-2162

Laboratory of Molecular Biology
Chief
Dr. Ira Pastan
301-496-4797

Mouse Cancer Genetics Program
Chief
Vacant
301-846-1260

Laboratory of Comparative
Carcinogenesis
Chief
Dr. Larry Keefer
301-846-1467

Laboratory of Molecular Cell Biology
Chief
Dr. Carl Wu
301-496-3029

Laboratory of Molecular
Pharmacology
Chief
Dr. Yves Pommier
301-496-5944

Laboratory of Nanobiology
Program
Chief
Dr. Robert Blumenthal
301-846-5532

Surgery Branch
Chief
Dr. Steven Rosenberg
301-496-4164

Cancer and Developmental Biology
Laboratory
Chief
Dr. Colin Stewart
301-846-1755

Laboratory of Pathology
Acting Chief
Dr. Elaine Jaffe
301-496-3185

Metabolism Branch
Chief
Dr. Thomas Waldmann
301-496-6653

Molecular Targets Drug
Development Program
Chief
Dr. James McMahon
301-846-5391

Experimental Transplantational
and Immunology Branch
Chief
Dr. Ronald Gress
301-496-6898

Genetics Branch
Chief
Dr. Michael Kuehl
301-496-0901

Neuro-Oncology Branch
Chief
Dr. Howard Fine
301-435-4024

Urologic Oncology Branch
Chief
Dr. W. Marston Linehan
301-496-6353

Laboratory of Population Genetics
Chief
Dr. Kenneth Buetow
301-435-8953

**Center for Cancer Research
Office of the Director**

Director

Dr. Robert Wiltrout

301-496-4345

Acting Scientific Director for Clinical Sciences

Dr. Lee Helman

301-496-4257

Deputy Directors

Dr. Richard Alexander Dr. Stuart Yuspa

Dr. Jeffrey Strathern Dr. Douglas Lowy

301-496-4346

Vaccine Branch
Chief
Dr. Jay Berzofsky
301-496-6824

Laboratory of Cellular Oncology
Chief
Dr. Douglas Lowy
301-496-9513

Experimental Immunology
Branch
Chief
Dr. Alfred Singer
301-496-5461

Laboratory of Cell Biology
Chief
Dr. Michael Gottesman
301-496-1530

Pediatric Oncology Branch
Chief
Dr. Lee Helman
301-496-4257

Radiation Oncology Branch
Acting Chief
Dr. James Mitchell
301-496-5457

Laboratory of Genomic Diversity
Chief
Dr. Stephen O'Brien
301-846-1296

Laboratory of Cell Regulation
and Carcinogenesis
Chief
Dr. Glenn Merlino
301-496-4270

HIV Drug Resistance Program
Chief
Dr. John Coffin
301-846-5943

Cell and Cancer Biology Branch
Chief
Dr. Kathleen Kelly
301-435-4651

Radiation Biology Branch
Chief
Dr. James Mitchell
301-496-7511

Laboratory of Medicinal
Chemistry
Chief
Dr. Victor Marquez
301-846-5954

Laboratory of Immune Cell
Biology
Chief
Dr. Jonathan Ashwell
301-496-4931

HIV DRP Laboratory of
Retroviral Replication
Chief
Dr. Stephen Hughes
301-846-1180

Laboratory of Protein Dynamics
and Signaling
Chief
Dr. Allan Weissman
301-846-1222

Macromolecular Crystallography
Laboratory
Chief
Dr. Alexander Wlodawer
301-846-5036

Laboratory of Receptor Biology
and Gene Expression
Chief
Dr. Gordon Hager
301-496-9867

Basic Research Laboratory
Chief
Dr. Douglas Lowy
301-496-9513

HIV DRP Laboratory of
Resistance Mechanisms
Chief
Dr. Stuart LeGrice
301-846-5943

Gene Regulation and
Chromosome Biology
Laboratory
Chief
Dr. Jeffrey N. Strathern
301-846-1274

Laboratory of Biosystems and
Cancer
Acting Chief
Dr. J. Vladimir Larionov
301-594-8466

Laboratory of Metabolism
Chief
Dr. Frank Gonzalez
301-435-5587

Laboratory of Experimental
Immunology
Chief
Dr. John Ortaldo
301-846-1323

Laboratory of Molecular
Immunoregulation
Chief
Dr. Joost Oppenheim
301-846-1551

Medical Oncology Branch
Acting Chief
Dr. Ronald Gress
301-496-1791

HIV and AIDS Malignancy
Branch
Chief
Dr. Robert Yarchoan
301-496-0328


Molecular Therapeutics
Program
Chief
Dr. Patricia Steeg
301-207-2732

Structural Biophysics
Laboratory
Chief
Dr. R. Andrew Byrd
301-846-1407

Laboratory of Human
Carcinogenesis
Chief
Dr. Curtis Harris
301-496-2048

Dermatology Branch
Chief
Dr. Mark Udey
301-496-1741

Molecular Imaging Program
Chief
Dr. Peter Choyke
301-451-6039



**Division of Cancer Prevention
Office of the Director**

Director
Dr. Peter Greenwald
301-496-6616

Acting Deputy Director
Dr. Leslie Ford
301-496-0265

Associate Director for Clinical Research
Dr. Leslie Ford
301-496-0265

Office of Preventive Oncology
Chief
Dr. Douglas Weed
301-496-8640

**Chemoprevention Agent
Development Research Group**
Chief
Dr. James Crowell
301-496-8563

**Community Oncology and
Prevention Trials Research
Group**
Chief
Dr. Lori Minasian
301-496-8541

**Breast & Gynecologic Cancer
Research Group**
Chief
Dr. Karen Johnson
301-496-8526

**Prostate & Urologic Cancer
Research Group**
Chief
Dr. Howard Parnes
301-594-0920

**Early Detection
Research Group**
Chief
Dr. Christine Berg
301-496-8544

**Biometry Research
Group**
Chief
Dr. Phillip Prorok
301-496-8556


**Gastrointestinal & Other Cancer
Research Group**
Acting Chief
Dr. Asad Umar
301-594-2684

**Lung & Upper Aerodigestive
Cancer Research Group**
Chief
Dr. Eva Szabo
301-435-1595

**Nutritional Science
Research Group**
Chief
Dr. John Milner
301-496-8573

**Basic Prevention Science
Research Group**
Acting Chief
Dr. John Gohagan
301-496-3982

**Cancer Biomarkers
Research Group**
Chief
Dr. Sudhir Srivastava
301-435-1594



Division of Cancer Treatment and Diagnosis

Office of the Director

Director

Dr. James H. Doroshow
301-496-4291

Deputy Director

Dr. Joseph Tomaszewski
301-496-6711

Biometrics Research Branch
Chief
Dr. Richard Simon
301-496-4836

Radiation Research Program
Associate Director
Dr. C. Norman Coleman
301-496-5457

Radiotherapy Development Branch
Chief
Dr. Francis Mahoney
301-496-9360

Molecular Therapeutics Branch
Chief
Dr. Philip Tofilon
301-496-6336

Clinical Radiation Oncology Branch
Chief
Vacant
301-496-6111

Cancer Therapy Evaluation Program
Associate Director
Dr. Michael Christian
301-496-6138

Investigational Drug Branch
Acting Chief
Dr. Anthony Murgo
301-496-1196

Clinical Investigations Branch
Chief
Dr. Jeffrey Abrams
301-496-2522

Pharmaceutical Management Branch
Chief
Mr. Charles Hall
301-496-5725

Regulatory Affairs Branch
Chief
Dr. Dale Shoemaker
301-496-7912

Clinical Trials Monitoring Branch
Chief
Ms. Joan Mauer
301-496-0510

Clinical Grants and Contracts Branch
Chief
Dr. Roy Wu
301-496-8866

Developmental Therapeutics Program
Associate Director
Dr. Jerry M. Collins
301-496-8777
Deputy Associate Director
Vacant

Information Technology Branch
Chief
Dr. Dan Zaharevitz
301-496-8747

Biological Testing Branch
Chief
Dr. Melinda Hollingshead
301-846-5065

Biological Resources Branch
Chief
Dr. Stephen Creekmore
301-846-1098

Toxicology and Pharmacology Branch
Chief
Dr. Joseph Tomaszewski
301-496-8777

Screening Technologies Branch
Chief
Dr. Robert Shoemaker
301-846-6845

Natural Products Branch
Chief
Vacant
301-846-5387

Drug Synthesis and Chemistry Branch
Chief
Dr. Ven Narayanan
301-496-8795

Grants & Contracts Operations Branch
Chief
Dr. Mary Wolpert-DeFilippes
301-496-8783

Pharmaceutical Resources Branch
Chief
Dr. Rao Vishnuvajjala
301-496-8780

Cancer Diagnosis Program
Associate Director
Dr. Sheila Taube
301-496-8639

Diagnostics Evaluation Branch
Acting Chief
Dr. James Jacobson
301-402-4185

Resources Development Branch
Chief
Vacant
301-496-7147

Diagnostic Biomarkers and Technology Branch
Chief
Dr. James Jacobson
301-402-4185

Cancer Imaging Program
Associate Director
Dr. Daniel Sullivan
301-496-9531

Diagnostic Imaging Branch
Chief
Dr. C. Carl Jaffe
301-435-9184

Molecular Imaging Branch
Chief
Vacant
301-496-9531

Image-Guided Intervention Branch
Chief
Vacant
301-496-9531

Imaging Technology Development Branch
Chief
Dr. Laurence Clarke
301-496-9531

**Division of Cancer Biology
Office of the Director**

Director
Dr. Dinah S. Singer
301-496-8636

Deputy Director
Dr. John A. Sogn
301-496-8636

Cancer Etiology Branch
Chief
Dr. Jack Gruber
301-496-9740

**Tumor Biology and Metastasis
Branch**
Chief
Dr. Suresh Mohla
301-435-1878

**Cancer Immunology and Hematology
Branch**
Chief
Dr. R. Allan Mufson
301-496-7815

**DNA and Chromosome Aberrations
Branch**
Chief
Dr. Judith Mietz
301-496-9326

Cancer Cell Biology Branch
Chief
Dr. Barbara Spalholz
301-496-7028

**Structural Biology and Molecular
Applications Branch**
Chief
Dr. Daniel Gallahan
301-435-5226

**Division of Extramural
Activities**

Director
Dr. Paulette S. Gray
301-496-5147

Acting Deputy Director
Dr. Paulette S. Gray
301-496-5147

Assistant Director
Dr. Cedric W. Long
301-496-9138

**Office of Extramural
Applications**
Associate Director
Mr. James W. Seach
301-496-5147

**Office of Grant Program
Coordination**
Chief
Vacant
301-435-5655

**Office of Referral, Review and
Program Coordination**
Associate Director
Ms. Diane Bronzert
301-435-5655

**Applied Information
Systems Branch**
Chief
Mr. James W. Seach
301-496-7047

**Research Analysis and
Evaluation Branch**
Chief
Ms. Marilyn Gaston
301-594-1111

**Research Programs
Review Branch**
Chief
Dr. Olivia T. Bartlett
301-594-2501

**Special Review and
Logistics Branch**
Chief
Dr. Kirt J. Vener
301-496-7174

**Program Coordination and
Referral Branch**
Chief
Dr. Christopher Hatch
301-594-1403

**Resources and Training
Review Branch**
Chief
Dr. David Maslow
301-496-2330

Number of Deaths for the Five Leading Cancer Sites by Age Group and Sex

All Ages		Under 15		15-34		35-54		55-74		75+	
Male	Female	Male	Female	Male	Female	Male	Female	Male	Female	Male	Female
Lung & Bronchus 89,906	Lung & Bronchus 68,084	Leukemia 279	Leukemia 226	Leukemia 531	Breast 421	Lung & Bronchus 8,650	Breast 9,024	Lung & Bronchus 47,250	Lung & Bronchus 33,047	Lung & Bronchus 33,912	Lung & Bronchus 28,759
Prostate 29,554	Breast 41,619	Brain & ONS 240	Brain & ONS 218	Brain & ONS 368	Leukemia 305	Colon & Rectum 3,177	Lung & Bronchus 6,189	Colon & Rectum 12,165	Breast 16,445	Prostate 21,001	Colon & Rectum 16,188
Colon & Rectum 27,990	Colon & Rectum 27,793	Endocrine 98	Endocrine 76	NHL 253	Brain & ONS 273	Liver & IBD 2,067	Colon & Rectum 2,475	Prostate 8,107	Colon & Rectum 8,987	Colon & Rectum 12,464	Breast 15,729
Pancreas 15,060	Pancreas 15,717	Bone & Joints 49	Soft Tissue 34	Soft Tissue 181	Cervix 217	Pancreas 1,877	Ovary 2,081	Pancreas 7,357	Ovary 6,460	Pancreas 5,784	Pancreas 8,410
Leukemia 12,104	Ovary 14,657	Soft Tissue 44	Bone & Joints 33	Colon & Rectum 180	Colon & Rectum 142	Brain & ONS 1,872	Cervix 1,523	Esophagus 5,334	Pancreas 6,067	Leukemia 5,507	Ovary 6,004

Source: National Center for Health Statistics (NCHS) Public -use file for 2003 deaths.
NHL = Non Hodgkin's Lymphoma

Relationship of Cancer to the Leading Causes of Death in the United States

Rank	Cause	Number of Deaths	Age Adjusted Rate*	Percent of Total Deaths
	All Causes	2,447,946	830.5	100.0%
1	Heart Disease	685,054	231.5	28.0%
2	CANCER	556,890	190.1	22.7%
3	Cerebrovascular Diseases	157,687	53.3	6.4%
4	Emphysema, Bronchitis & Asthma	126,380	43.3	5.2%
5	Accidents	109,201	37.2	4.5%
6	Diabetes Mellitus	74,216	25.3	3.0%
7	Pneumonia & Influenza	65,161	21.9	2.7%
8	Alzheimers	63,457	21.2	2.6%
9	Nephritis & Nephrosis	42,451	14.4	1.7%
10	Septicemia	34,066	11.6	1.4%
11	Suicide and Self-Inflicted Injury	31,477	10.7	1.3%
12	Symptoms, Signs and Ill-Defined Conditions	31,332	10.6	1.3%
13	Chronic Liver Dis and Cirrhosis of the Liver	27,500	9.3	1.1%
14	Hypertension without Heart Disease	21,940	7.4	0.9%
15	Homicide and Legal Intervention	18,114	6.2	0.7%
	Other and Ill-Defined	403,020	136.6	16.5%

Source: NCHS Public-use file for 2003 deaths.
* Age adjusted rate per 100,000 Population

Estimated New Cancer Cases and Deaths by Sex for All Races 2006

Primary Site	Estimated New Cases			Estimated Deaths		
	Total	Male	Female	Total	Male	Female
All Sites	1,399,790	720,280	679,510	564,830	291,270	273,560
Oral Cavity and Pharynx	30,990	20,180	10,810	7,430	5,050	2,380
Tongue	9,040	5,870	3,170	1,780	1,150	630
Mouth	10,230	5,440	4,790	1,870	1,100	770
Pharynx	8,950	6,820	2,130	2,110	1,540	570
Other Oral Cavity	2,770	2,050	720	1,670	1,260	410
Digestive System	263,060	137,630	125,430	136,180	75,210	60,970
Esophagus	14,550	11,260	3,290	13,770	10,730	3,040
Stomach	22,280	13,400	8,880	11,430	6,690	4,740
Small Intestine	6,170	3,160	3,010	1,070	560	510
Colon *	106,680	49,220	57,460	55,170	27,870	27,300
Rectum	41,930	23,580	18,350			
Anus, Anal Canal, & Anorectum	4,660	1,910	2,750	660	220	440
Liver and Intrahepatic Bile Duct	18,510	12,600	5,910	16,200	10,840	5,360
Gallbladder & Other Biliary	8,570	3,720	4,850	3,260	1,280	1,980
Pancreas	33,730	17,150	16,580	32,300	16,090	16,210
Other Digestive	5,980	1,630	4,350	2,320	930	1,390
Respiratory System	186,370	101,900	84,470	167,050	93,820	73,230
Larynx	9,510	7,700	1,810	3,740	2,950	790
Lung and Bronchus	174,470	92,700	81,770	162,460	90,330	72,130
Other Respiratory	2,390	1,500	890	850	540	310
Bones and Joints	2,760	1,500	1,260	1,260	730	530
Soft Tissues	9,530	5,720	3,810	3,500	1,830	1,670
Skin (excl. basal & squamous)	68,780	38,360	30,420	10,710	6,990	3,720
Melanoma-skin	62,190	34,260	27,930	7,910	5,020	2,890
Other non-epithelial skin	6,590	4,100	2,490	2,800	1,970	830
Breast	214,640	1,720	212,920	41,430	460	40,970
Genital Organs	321,490	244,240	77,250	56,060	28,000	28,060
Cervix Uteri	9,710		9,710	3,700		3,700
Endometrium (uterus)	41,200		41,200	7,350		7,350
Ovary	20,180		20,180	15,310		15,310
Vulva	3,740		3,740	880		880
Vagina and other genital organs, female	2,420		2,420	820		820
Prostate	234,460	234,460		27,350	27,350	
Testis	8,250	8,250		370	370	
Penis and other genital organs, male	1,530	1,530		280	280	
Urinary System	102,740	70,940	31,800	26,670	17,530	9,140
Urinary Bladder	61,420	44,690	16,730	13,060	8,990	4,070
Kidney and Renal Pelvis	38,890	24,650	14,240	12,840	8,130	4,710
Ureter and other urinary organs	2,430	1,600	830	770	410	360
Eye and Orbit	2,360	1,230	1,130	230	110	120
Brain and Other Nervous System	18,820	10,730	8,090	12,820	7,260	5,560
Endocrine Glands	32,260	8,690	23,570	2,290	1,020	1,270
Thyroid	30,180	7,590	22,590	1,500	630	870
Other Endocrine	2,080	1,100	980	790	390	400
Lymphomas and Myelomas	66,670	34,870	31,800	20,330	10,770	9,560
Hodgkin Disease	7,800	4,190	3,610	1,490	770	720
Non-Hodgkin Lymphoma	58,870	30,680	28,190	18,840	10,000	8,840
Multiple Myeloma	16,570	9,250	7,320	11,310	5,680	5,630
Leukemia	35,070	20,000	15,070	22,280	12,470	9,810
Lymphocytic Leukemias	13,950	8,430	5,520	6,150	3,490	2,660
Myeloid Leukemias	16,430	8,900	7,530	9,640	5,390	4,250
Other Leukemias	4,690	2,670	2,020	6,490	3,590	2,900
All Other Sites	27,680	13,320	14,360	45,280	24,340	20,940

Source: Cancer Facts & Figures-2006, American Cancer Society (ACS), Atlanta, Georgia 2006.

Excludes basal and squamous cell skin and in situ carcinomas except urinary bladder.

Incidence projections are based on rates from the NCI SEER Program 1979-2002.

Estimated deaths come from the NCHS public use data file for the total US.

* Estimated deaths for colon & rectum cancers are combined.

The Cost of Cancer

Cancer treatment spending has risen but remains stable in proportion to total U.S. treatment spending.

The financial costs of cancer treatment are a burden to people diagnosed with cancer, their families, and society as a whole. Cancer treatment accounted for about \$74.0 billion in 2005. This is just under 5 percent of total U.S. spending for medical treatment. The additional economic burden of cancer due to morbidity and premature mortality is estimated to be \$135.9 billion resulting in a total economic burden of cancer in 2005 of \$209.9 billion.

Year	Amount (\$ in millions)	Percent of All Health Care Expenditures
1963	\$1,279	4.35%
1972	3,872	4.96%
1980	13,049	6.01%
1985	18,104	4.81%
1990	27,458	4.46%
1995	41,200	4.69%
2002	60,900	4.57%
2004	72,006	4.67%
2005	74,000	4.60%


Sources:

Ries LAG, Eisner MP, Kosary CL, Hankey BF, Miller MA, Clegg L, Mariotto A, Feuer EJ, Edwards BK (eds). *SEER Cancer Statistics Review, 1975-2001*, National Cancer Institute, Bethesda, MD

Brown ML, Riley GF, SchusslerN, Etzioni RD. Estimating health care costs related to cancer treatment from SEER-Medicare data. *Medical care* 2002 Aug; 40 (8 Suppl):IV-104-17.


NHLBI Fact Book - 2003, 2005. National Heart, Lung and Blood Institute, Bethesda. Estimates by NHLBI; data from NCHS, HCFA, the Bureau of the Census, and the Institute for Health and Aging, University of California, San Francisco.

**Average Years of Life Lost
Per Person Dying of Cancer
All Races, Both Sexes, 2003**



Source: NCHS public-use data and 2003 life tables.

5 Year Relative Survival Rates by Cancer Site
SEER Program 1996-2002
Males and Females




Data From NCI SEER Program
<http://www.seer.cancer.gov/>

* The relative cumulative rate increased from a prior interval and has been adjusted.
 The 5-year relative survival rate is calculated using 60 monthly intervals.

Cancer Incidence Rates


Annual Percent Changes from 1992 to 2003



* The annual percent change is significantly different from zero ($p < .05$).

Cancer Mortality Rates

Annual Percent Changes from 1992 to 2003



* The annual percent change is significantly different from zero (p<.05).

Cancer Incidence Rates By Race

SEER, 1992-2003

Cancer Site	Incidence Rates per 100,000				
	Blacks	Whites	Hispanics	Asian/ Pacific Islander	American Indian/ Alaska Native
All Sites	524.3	482.2	349.4	334.7	262.5
Males	709.7	570.4	422.8	388.9	297.8
Females	401.2	424.8	304.5	297.0	239.4
Oral Cavity and Pharynx	12.5	10.9	6.5	8.7	7.7
Esophagus	7.5	4.3	3.0	2.8	3.2
Stomach	13.5	7.7	13.2	16.9	10.6
Colon and Rectum	62.5	53.2	38.2	46.2	36.7
Colon excluding Rectum	48.4	38.6	26.4	31.4	26.5
Rectum and Rectosigmoid Junction	14.2	14.6	11.8	14.9	10.2
Liver and IHBD	6.8	4.6	8.9	13.8	7.5
Pancreas	15.9	10.9	9.8	9.2	7.7
Larynx	6.6	3.9	2.8	1.7	1.6
Lung and Bronchus	81.1	63.5	33.1	42.3	37.7
Males	121.5	80.8	46.7	60.5	51.3
Females	53.6	51.3	23.8	28.2	27.2
Melanoma of the Skin	1.0	19.5	3.9	1.3	2.3
Breast (females)	120.2	137.3	86.5	91.5	63.4
<50 years	43.2	42.9	31.0	37.4	22.8
50+ years	322.0	384.6	231.7	233.3	169.5
Cervix Uteri	12.3	9.2	16.7	10.1	7.3
Corpus and Uterus, NOS	18.5	25.8	16.3	16.7	11.3
Ovary	10.4	15.0	11.7	10.2	9.3
Prostate	280.7	174.4	140.7	103.0	66.3
Testis	1.3	6.0	3.4	1.9	2.9
Urinary Bladder	12.5	22.4	10.7	9.6	5.2
Kidney and Renal Pelvis	13.1	11.6	10.9	6.2	12.0
Brain and Other Nervous System	4.1	7.1	5.0	3.5	2.5
Thyroid	4.1	7.2	6.4	7.9	4.3
Hodgkin lymphoma	2.4	2.9	2.3	1.1	0.6
Non-Hodgkin lymphoma	14.5	20.3	16.0	13.5	8.5
All Sites Except Lung and Bronchus	443.3	418.7	316.4	292.4	224.8
Males	588.2	489.6	376.1	328.3	246.5
Females	347.6	373.4	280.7	268.8	212.1

Data source: NCI SEER Program.

NCI's SEER Program, adjusted to the 2000 US population age distribution. Rates for Hispanics exclude cases diagnosed in Alaska, Hawaii and Rural Georgia.

Cancer Mortality Rates By Race United States, 1992-2003

Cancer Site	Mortality Rates per 100,000				
	Blacks	Whites	Hispanics	Asian/ Pacific Islander	American Indian/ Alaska Native
All Sites	257.0	199.7	136.4	123.9	133.7
Males	355.9	250.5	173.6	153.8	163.0
Females	198.2	167.2	111.6	101.7	114.3
Oral Cavity and Pharynx	4.6	2.8	1.8	2.5	2.3
Esophagus	7.2	4.1	2.4	2.1	2.7
Stomach	9.4	4.3	7.3	9.5	5.4
Colon and Rectum	28.4	20.9	14.1	13.3	13.6
Liver and IHBD	6.1	4.1	7.3	10.8	5.6
Pancreas	14.3	10.3	8.4	7.4	6.2
Larynx	2.9	1.3	1.0	0.5	1.0
Lung and Bronchus	66.4	56.7	25.3	28.4	35.8
Males	107.6	78.6	39.8	40.8	48.7
Females	39.4	41.2	14.9	19.0	26.4
Melanoma of the Skin	0.5	3.0	0.8	0.4	0.7
Breast (females)	36.0	27.7	17.5	12.8	14.4
<50 years	10.8	6.0	4.7	3.9	3.1
50+ years	102.0	84.5	51.2	36.3	44.0
Cervix Uteri	6.0	2.7	3.7	2.9	3.1
Corpus and Uterus, NOS	7.0	3.9	3.2	2.2	2.4
Ovary	7.5	9.3	6.2	4.8	5.2
Prostate	72.2	30.6	24.1	13.8	21.1
Testis	0.2	0.3	0.3	0.1	0.2
Urinary Bladder	4.0	4.5	2.4	1.8	1.7
Kidney and Renal Pelvis	4.2	4.3	3.8	1.9	4.8
Brain and Other Nervous System	2.7	5.0	2.9	1.9	2.0
Thyroid	0.4	0.5	0.6	0.6	0.3
Hodgkin lymphoma	0.5	0.5	0.5	0.2	0.2
Non-Hodgkin lymphoma	5.6	8.6	6.4	5.2	4.3
All Sites Except Lung and Bronchus	190.7	143.0	111.1	95.5	98.0
Males	248.2	171.9	133.9	113.0	114.2
Females	158.8	126.0	96.7	82.7	87.9

Data source: NCHS public-use data files. Rates for Hispanics exclude cases diagnosed in Connecticut, Maine, Maryland, Minnesota, New Hampshire, New York, North Dakota, Oklahoma, and Vermont.

**The Prevalence of Cancer:
Estimated Number of Persons
Diagnosed With Cancer
United States, 2002**

Primary Site	Estimated Prevalence		
	Total ^	Males	Females
ALL SITES^a	10,146,324	4,503,895	5,642,429
Brain and Other Nervous System	105,960	56,865*	49,095*
Breast	2,290,049	11,780	2,278,269
Cervix	223,441*		223,441*
Colon and Rectum	1,051,682	505,267	546,415
Corpus and Uterus	571,854		571,854
Esophagus	23,402	17,651	5,751
Hodgkin Lymphoma	145,501	76,257	69,244
Kidney and Renal Pelvis	221,270	130,654	90,616
Larynx	97,903	78,348	19,555
Leukemia	189,865	106,434	83,431
Acute Lymphocytic Leukemia	44,730#	24,523#	20,207#
Lung and Bronchus	350,679	174,384	176,295
Melanoma of the Skin	629,822	304,097	325,725
Non-Hodgkin Lymphoma	347,039	180,337	166,702
Oral Cavity and Pharynx	231,799	147,272	84,527
Ovary	169,875		169,875
Pancreas	26,079	12,491	13,588
Prostate	1,831,929	1,831,929	
Stomach	59,311	34,258	25,053
Testis	164,009	164,009	
Thyroid	327,403	74,985	252,418
Urinary Bladder	499,199	367,550	131,649
Childhood (0-19 yrs)	215,915#	110,475#	105,440#

Source: U.S. 2002 cancer prevalence rates are based on 2002 cancer prevalence proportions from the nine SEER registries and 1/1/2002 population estimates based on the average of 2001 and 2002 population estimates from the U.S. Bureau of the Census.

^a The All Sites figures are estimates based on all cancer sites, not just those listed here.

[^] The total column represents prevalence estimates using the completeness index method (Capocaccia et. al. 1997, Merrill et. al. 2000). Totals are obtained by summing males and females and not by modeling.

* Completeness index was approximated using empirical data from historical Connecticut tumor registry by age at prevalence

Current methodology does not allow for the estimation of complete prevalence for childhood cancer or acute lymphocytic leukemia. Estimates shown are 27 year limited-duration prevalence.

Fiscal Year 2005 Budget

(Dollars in Thousands)

A. Actual Obligations Resulting From Appropriated Funds:

FY 2005 Appropriation	\$4,865,525
Labor/HHS/ ED Recission	-1,353
Across the Board .80% Reduction	-38,914
NIH 1% Transfer Assessment for NIH Roadmap Activities	-30,505
Lapse	-9
Actual Obligations Subtotal	4,794,744

B. Reimbursable Obligations:


Reimbursements	15,528
-----------------------	---------------

C. Total NCI Obligations: \$4,810,272 *

*EXCLUDES projects awarded with Stamp Out Breast Cancer funds.

Program Structure Fiscal Year 2005

(Dollars in Thousands)




Budget Activity	Amount	Percent
Research:		
Cancer Causation	\$1,101,861	23.0%
Detection and Diagnosis Research	368,144	7.7%
Treatment Research	1,069,308	22.3%
Cancer Biology	786,200	16.4%
Subtotal Research	3,325,513	69.4%
Resource Development:		
Cancer Centers Support	455,241	9.5%
Research Manpower Development	179,501	3.7%
Buildings and Facilities	7,936	0.2%
Subtotal Resource Development	642,678	13.4%
Cancer Prevention and Control	510,829	10.7%
Program Management and Support	315,724	6.5%
*Total NCI	4,794,744	100.0%

*EXCLUDES projects awarded with Stamp Out Breast Cancer funds.

Extramural Funds Fiscal Year 2005

(Dollars in Thousands)



Mechanism	Amount	Percent
Contracts:		
R&D Contracts	\$282,270	7.5%
Interagency Agreements	83,942	2.2%
Cancer Control Contracts	130,650	3.5%
Buildings and Facilities	7,936	0.2%
Construction Contracts	0	0.0%
Subtotal Contracts	504,798	13.4%
Grants:		
Research Project Grants	2,188,884	58.3%
Cancer Centers/Specialized Centers/SPORES	454,252	12.1%
NRSA	67,299	1.8%
Other Research Grants	308,972	8.2%
Cancer Control Grants	231,809	6.2%
Construction Grants	0	0.0%
Subtotal Grants	3,251,216	86.6%
Total Extramural Funds	3,756,014	100.0%
Total Intramural/RMS/Control Inhouse	1,038,730	
*Total NCI	\$4,794,744	

*EXCLUDES projects awarded with Stamp Out Breast Cancer funds.

NCI Obligations by Mechanism, Fiscal Year 2005

(Dollars in Thousands)

		Number	Amount	% of Total
Research Project Grants	Non-Competing	3,855	1,600,584	33.4%
	Administrative Supplements	(292)	50,655	1.1%
	Competing	1,292	439,870	9.2%
	Subtotal, without SBIR/STTR Grants	5,147	2,091,109	43.6%
	SBIR/STTR Grants	265	97,775	2.0%
	Subtotal, Research Project Grants	5,412	2,188,884	45.7%
Centers & SPORES	Cancer Centers Grants-P30	61	255,263	5.3%
	SPORES-P20/P50	57	133,025	2.8%
	Other Specialized Centers	34	65,964	1.4%
	Subtotal, Centers	152	454,252	9.5%
Other Research	Career Program			0.0%
	Temin & Minority Mentored Awards-K01	127	17,734	0.4%
	Estab. Inv. Award-K05	20	2,554	0.1%
	Preventive Oncology-K07	110	13,529	0.3%
	Clinical Investigator-K08	141	17,841	0.4%
	Clinical Oncology-K12	13	7,436	0.2%
	Transitional Career Development-K22	35	5,344	0.1%
	Mentored Patient Oriented RCDA-K23	60	7,533	0.2%
	Mid-Career Invest. & Patient Orient. Res-K24	16	2,306	0.1%
	Mentored Quant. Res Career-K25	9	1,227	0.0%
	Inst. Curr. Award-K30	0	1,147	0.0%
	Subtotal, Career Program	531	76,652	1.6%
	Cancer Education Program-R25	101	34,581	0.7%
	Clinical Cooperative Groups-U10	63	142,847	3.0%
	Minority Biomedical Support-S06		3,367	0.1%
	Scientific Evaluation-U09/T09	0	8,621	0.2%
	Continuing Education	3	338	0.0%
	Resource Grants-R24/U24	51	28,178	0.6%
	Explor Coop Agreement-U56	29	12,487	0.3%
	Conference Grants-R13	96	1,900	0.0%
	Subtotal, Other Research Grants	874	308,972	6.4%
	Subtotal, Research Grants		6,438	2,952,108
NRSA Fellowships	<i>Trainees:</i>	1,469	67,299	1.4%
R&D Contracts	R&D Contracts	286	344,336	7.2%
	SBIR Contracts	32	6,721	0.1%
	Subtotal, Contracts	318	351,056	7.3%
Intramural Research	Program	1,832	586,990	12.2%
	NIH Management Fund/SSF Assessment		124,019	2.6%
	Subtotal, Intramural Research	<i>FTEs:</i> 1,832	711,009	14.8%
RMS	Research Mgmt and Support	612	145,709	3.0%
	NIH Management Fund/SSF Assessment		27,993	0.6%
	Subtotal, RMS	<i>FTEs:</i> 612	173,702	3.6%
Cancer Prevention and Control	Cancer Control Grants	221	231,810	4.8%
	Cancer Control Contracts	178	145,806	3.0%
	Inhouse	410	145,232	3.0%
	NIH Management Fund/SSF Assessment		8,786	0.2%
	Subtotal, Prevention and Control	<i>FTEs:</i> 410	531,634	11.1%
Buildings and Facilities			7,936	0.2%
Construction			0	0.0%
*Total NCI	<i>FTEs:</i>	2,854	4,794,744	100.0%

*EXCLUDES projects awarded with Stamp Out Breast Cancer funds.


Division Obligations by Mechanism, Fiscal Year 2005

(Dollars in Thousands)

CCR	DCEG	DCTD	DCB	DCCPS	DCP	DEA	OD	Research Grants	Program Support
								1,541,863	58,721
								50,655	
								439,870	
								2,032,388	58,721
								97,775	
								2,130,163	58,721
		5,019					250,244		
							133,025		
		4,732	14,667	9,409			37,156		
		9,751	14,667	9,409			420,425		
							17,734		
							2,554		
							13,529		
							17,841		
							7,436		
							5,344		
							7,533		
							2,306		
							1,227		
							1,147		
							76,652		
							34,581		
								142,847	
								3,367	
								8,621	
								338	
								28,178	
								12,487	
								1,900	
							34,581	197,739	0
		9,751	14,667	9,409			531,658	2,327,902	58,721
							67,299		
	18,664	108,393	2,395	29,709			129,695		55,480
	580	2,489	1,594	1,340	485		234		
	19,243	110,882	3,989	31,049	485		129,929		55,480
376,842	50,520	408					135,294		23,926
									124,019
376,842	50,520	408					135,294		147,945
		32,169	11,065			12,564	68,564		21,349
									27,993
		32,169	11,065			12,564	68,564		49,342
		19,506		52,193	132,533		27,577		
	5,932	9,548		33,254	73,663		23,409		
984	10,548	7,216		27,393	19,294		74,655		5,142
									8,786
984	16,480	36,271		112,840	225,491		125,641		13,928
							7,936		
377,826	86,243	189,480	29,721	153,297	225,975	12,564	1,066,321	2,327,902	325,416

NIH Management Fund, Service & Supply Fund, and GSA Rent Fiscal Year 2005

(Dollars in Thousands)



DISTRIBUTION OF NCI PAYMENT	Amount	Share of NCI
Clinical Center	\$90,987	56.6%
Center for Scientific Review	8,497	5.3%
Center for Information Technology	7,901	4.9%
Service & Supply Fund	13,740	8.5%
Other Research Services	13,537	8.4%
Other OD	26,136	16.3%
*Total Management Fund and SSF	160,798	100.0%
Other NIH Institutes Management Fund and SSF	529,853	
Total NIH Management Fund and SSF	\$690,651	

*Excludes GSA Rental Payments for Space which totaled \$42,449 in FY 2005

The Management Fund provides for the financing of certain common research and administrative support activities which are required in the operations of NIH:

Clinical Center: Admissions and followup, anesthesiology, diagnostic x-ray, nuclear medicine, clinical pathology, blood bank, rehabilitation medicine, pharmacy, medical records, nursing services, patient nutrition service, housekeeping services, laundry, and social work

Center for Scientific Review: Initial scientific review of applications, assignment of research grant applications to institutes

Center for Information Technology: Research and development program in which concepts and methods of computer science are applied to biomedical problems

GSA Rental Payments for Space: All building rental, including utilities and guard services.

Other Research Services: Procurement, safety, engineering, biomedical engineering, veterinary resources, and library

Service & Supply Fund: Animal support, collaborative research, conference services, hazardous waste management, interpreting services, library, occupational health and safety, property management support and radiation safety

Special Sources of Funds

CRADAs

As a result of the Federal Technology Transfer Act of 1986 (PL 99-502), government laboratories are authorized to enter into Cooperative Research and Development Agreements (CRADAs) with private sector entities. Licensing agreements are usually incorporated into the CRADA document which addresses patent rights attributable to research supported under the CRADA.

NCI CRADA Receipts Deposited to the U.S. Treasury
(Dollars in Thousands)

Fiscal Year	Carryover from Prior Year	Collections	Obligations
1995	2,448	2,811	1,395
1996	3,864	2,017	1,394
1997	4,486	13,378	6,639
1998	11,217	5,351	7,266
1999	9,302	3,645	4,707
2000	8,240	2,717	4,618
2001	6,339	5,295	2,770
2002	8,864	5,048	2,380
2003	11,533	5,221	5,361
2004	11,351	5,080	5,469
2005	10,962	6,858	4,253

Royalty Income

NCI retains a portion of the royalty income generated by the patents related to NCI-funded research. A major portion of this royalty income is used to reward employees of the laboratory, further scientific exchange and for education and training in accordance with the terms of the Federal Technology Transfer Act (PL 99-502). Receipts are also used to support costs associated with processing and collecting royalty income and for technology transfer efforts in NCI and NIH.

NCI Royalty Income Funding History
(Dollars in Thousands)

Years	Collections*	Inventor	
		Payments	Other
1995/1996	9,031	953	8,078
1996/1997	13,598	2,175	11,423
1997/1998	9,814	2,321	7,493
1998/1999	22,716	5,084	17,632
1999/2000	21,160	4,695	16,465
2000/2001	37,040	4,811	32,229
2001/2003	27,443	6,210	21,233
2002/2004	42,565	3,961	38,604
2003/2005	27,271	5,262	22,009
2004/2006	26,923	4,951	21,972
**2005/2007	34,086	5,000	29,086

* Does not include assessments by NIH.

**2005/2007 collections and payments are estimates.

Stamp Out Breast Cancer

The Stamp Out Breast Cancer Act (PL 105-41) was established in August 1997 and extended in July 2000 (PL 106-253) and again in November 2005 (PL 109-100). This act allows postal customers to contribute to funding for breast cancer research through their voluntary purchases of special rate postage stamps from the U.S. Postal Service. The Act required the USPS to transfer 70% to NIH and 30% to the DOD of the funds collected above the postage costs and administrative costs. As of November 2005, NCI has received \$33,561,283. NCI has used these funds for research projects directed towards breast cancer research. Thus far, two major programs have been funded -- the "Insight Awards to Stamp Out Breast Cancer" and the "Breast Cancer Research Stamp Exception Program." In FY 2005, 7 Awards for a total of \$2,987K were funded from Breast Cancer Stamp funds.

Funding for Various Research Areas


(Dollars in Millions)

The National Cancer Institute reports how appropriated funds are spent in a number of different categories or classifications including specific cancer sites, cancer types, diseases related to cancer, as well as types of research mechanisms. The table below represents funding levels for frequently requested research areas. These research areas do not represent the entire NCI research portfolio. Funding for these areas can overlap and do not add to the total NCI budget. For example, dollars for a clinical trial on breast cancer research would be included in both the Breast Cancer and the Clinical Trials lines in the table below. Similarly, a basic cancer research project may be relevant to cervical, uterine and ovarian cancers and relevant funding would be included in the figures for all three sites.

Disease Area	2001 Actual	2002 Actual	2003 Actual	2004 Actual	2005 Actual
Total NCI Budget	\$3,753.7	\$4,176.7	\$4,592.3	\$4,723.9	\$4,794.7
AIDS	237.8	254.4	263.4	267.0	265.9
Brain & CNS	80.7	95.2	111.5	132.3	107.2
Breast Cancer	475.2	522.6	548.7	566.2	560.1
Cervical Cancer	72.6	67.6	79.0	79.0	81.7
Clinical Trials	648.6	702.1	799.5	800.0	781.8
Colorectal Cancer	207.4	245.0	261.6	262.0	253.1
Head and Neck Cancers	50.0	58.9	77.7	88.2	89.5
Hodgkins Disease	10.2	11.8	16.5	17.4	17.2
Leukemia	154.0	177.2	200.9	214.7	220.6
Liver Cancer	54.5	62.5	63.7	63.0	60.5
Lung Cancer	206.5	237.5	273.5	276.5	266.1
Melanoma	71.8	82.3	90.7	94.9	102.9
Multiple Myeloma	19.7	20.8	26.3	23.9	28.2
Non Hodgkin's Lymphoma	79.5	85.6	95.2	99.6	107.0
Ovarian Cancer	76.9	93.5	99.4	99.5	97.7
Pancreatic Cancer	21.8	33.1	42.3	52.7	66.7
Prostate Cancer	258.0	278.4	305.2	308.5	309.0
Stomach Cancer	9.0	11.4	13.4	11.6	11.0
Uterine Cancer	18.8	23.1	25.5	27.0	31.1

Research Project Grants Number of Awards Fiscal Years 1996 - 2005

Includes Small Business Innovation Research and Small Business Technology Transfer Awards



*EXCLUDES projects awarded with Stamp Out Breast Cancer Funds.

RPGs Requested and Awarded Fiscal Years 1996 - 2005

(Dollars in Thousands)

Fiscal Year	Type	Requested		Awarded		Success Rate	
		No.	Amt.	No.	Amt.		
1996	Competing	New	3,071	\$733,313	682	\$142,249	27.5%
		Renewal	947	367,270	422	139,995	
		Supplement	10	1,921	5	694	
		Subtotal	4,028	1,102,504	1,109	282,938	
	Non-Competing			2,381	751,592		
	Total			3,490	1,034,530		
1997	Competing	New	3,328	\$828,653	815	\$160,763	29.2%
		Renewal	815	354,054	392	146,912	
		Supplement	14	3,136	5	755	
		Subtotal	4,157	1,185,843	1,212	308,430	
	Non-Competing			2,532	814,885		
	Total			3,744	1,123,315		
1998	Competing	New	3,054	\$797,477	847	\$189,746	32.8%
		Renewal	697	283,562	382	137,764	
		Supplement	18	4,299	6	1,421	
		Subtotal	3,769	1,085,338	1,235	328,931	
	Non-Competing			2,723	901,845		
	Total			3,958	1,230,776		
1999	Competing	New	3,905	\$1,091,110	1,088	\$237,187	31.8%
		Renewal	757	340,075	390	145,623	
		Supplement	12	3,882	6	2,353	
		Subtotal	4,674	1,435,067	1,484	385,163	
	Non-Competing			2,867	976,610		
	Total			4,351	1,361,773		
2000	Competing	New	4,116	\$1,253,002	957	\$251,628	27.2%
		Renewal	839	435,207	392	175,908	
		Supplement	11	2,379	2	231	
		Subtotal	4,966	1,690,588	1,351	427,767	
	Non-Competing			3,175	1,100,234		
	Total			4,526	1,528,001		
2001	Competing	New	4,342	\$1,374,538	1,050	\$290,707	27.3%
		Renewal	856	437,455	372	173,722	
		Supplement	29	11,108	6	1,214	
		Subtotal	5,227	1,823,101	1,428	465,643	
	Non-Competing			3,267	1,213,098		
	Total			4,695	1,678,741		
2002	Competing	New	4,539	\$1,407,475	1,142	\$302,217	28.4%
		Renewal	861	404,789	384	186,087	
		Supplement	42	8,512	21	3,499	
		Subtotal	5,442	1,820,776	1,547	491,803	
	Non-Competing			3,429	1,356,138		
	Total			4,976	1,847,941		
2003	Competing	New	5,323	\$1,675,039	1,222	\$347,446	26.5%
		Renewal	955	447,122	441	194,084	
		Supplement	20	4,671	5	1,338	
		Subtotal	6,298	2,126,832	1,668	542,868	
	Non-Competing			3,467	1,457,144		
	Total			5,135	2,000,012		
2004	Competing	New	6,558	\$2,045,451	1,333	\$339,925	23.6%
		Renewal	988	518,201	445	210,790	
		Supplement	24	8,337	7	2,196	
		Subtotal	7,570	2,571,989	1,785	552,911	
	Non-Competing			3,682	1,549,727		
	Total			5,467	2,102,638		
2005	Competing	New	6,357	\$2,239,503	1,086	\$309,507	19.2%
		Renewal	1,050	473,898	335	162,857	
		Supplement	22	6,147	7	1,185	
		Subtotal	7,429	2,719,548	1,428	473,549	
	Non-Competing			3,984	1,656,614		
	Total			5,412	2,130,164		

Includes Small Business Innovation Research and Small Business Technology Transfer Awards.

Success rate is the number of awarded grants divided by the number of awards requested.

The requested data excludes applications not recommended for further review.


Totals exclude Assessments for Program Evaluation and projects awarded with Stamp Out Breast Cancer Funds.

RPG Awards by Activity Code

Fiscal Years 1996 - 2005*

(Dollars in Thousands; Activity Code Descriptions on next page)

		R01	P01	R35	R37	R29	RFA	U01	U19	R03	R21	R33	R15	R55	R56	SBIR/ STTR	TOTAL
1996	#	1,964	144	65	110	388	268	226		85	46			14		180	3,490
	\$	504,398	182,609	62,550	37,070	41,170	66,102	88,962		5,443	9,599			984		35,643	1,034,530
1997	#	2,194	149	63	90	446	195	169		101	63			21		253	3,744
	\$	583,116	202,317	62,892	30,950	47,413	48,148	81,193		6,411	12,269			1,450		47,156	1,123,315
1998	#	2,454	160	57	75	485	132	157		97	76		2	14		249	3,958
	\$	672,873	228,854	57,712	27,212	52,136	42,750	79,370		6,069	11,782		127	684		51,207	1,230,776
1999	#	2,796	169	38	71	413	261	31		108	159	6	2	6		291	4,351
	\$	775,961	249,583	38,585	27,377	45,361	112,868	21,319		7,355	22,548	2,079	200	620		57,917	1,361,773
2000	#	3,011	179	21	60	314	269	18		100	223	20		5		306	4,526
	\$	898,764	286,234	19,413	24,688	34,769	132,872	13,617		7,034	32,897	10,074	99	450		67,090	1,528,001
2001	#	3,231	178	1	61	210	260	18		122	231	49	3	3		328	4,695
	\$	1,008,199	301,115	2,186	26,682	23,738	150,224	14,873		9,024	42,326	23,883	358	300		75,833	1,678,741
2002	#	3,376	173		65	112	267	17		186	308	79	10	9		374	4,976
	\$	1,093,908	317,632		29,445	12,471	177,195	17,531		14,115	57,633	39,317	1,477	850		86,367	1,847,941
2003	#	3,573	178		70	14	252	27		203	360	81	21			356	5,135
	\$	1,207,387	336,607		35,360	1,584	173,342	31,126		15,207	67,742	37,714	3,086			90,857	2,000,012
2004	#	3,780	177		73	0	233	26		240	425	96	20			397	5,467
	\$	1,277,185	344,489		37,888	53	168,539	31,377		18,067	77,970	42,931	4,560			99,579	2,102,638
2005	#	3,848	176		74		254	30	1	223	430	88	20	2	1	265	5,412
	\$	1,312,762	338,660		40,007		171,403	34,100	1,049	16,894	76,566	36,250	4,091	200	407	97,775	2,130,164



*EXCLUDES projects awarded with the Stamp Out Breast Cancer Funds and Program Evaluation.

Activity Code Descriptions

R01	Research Project (Traditional) discrete, specified, circumscribed project to be performed by the named investigator(s) in an area representing his/her specified interest and competencies.
P01	Research Program Projects broadly based, multidisciplinary, often long-term, research program which has a specific major objective or a basic theme. A program project is directed toward a range of problems having a central research focus in contrast to the usually narrower thrust of the traditional research project.
R35	Outstanding Investigator Grants long-term support to an experienced investigator with an outstanding record of research productivity. This support is intended to encourage investigators to embark on long-term projects of unusual potential in a categorical program area.
R37	Method to Extend Research in Time (MERIT) Award long-term grant support to investigators whose research competence and productivity are distinctly superior and who are highly likely to continue to perform in an outstanding manner. Investigators may not apply for a MERIT award. Program staff and/or members of the cognizant National Advisory Council/Board will identify candidates for the MERIT award during the course of review of competing research grant applications prepared and submitted in accordance with regular PHS requirements.
R29	First Independent Research Support and Transition (FIRST) Award sufficient initial period of research support for newly independent biomedical investigators to develop their research capabilities and demonstrate the merit of their research ideas.
RFA	Request for Applications A formal statement inviting grant or cooperative agreement applications in a well-defined scientific area to accomplish specific program purposes and indicates the amount of funds set aside for the competition and/or the estimated number of awards to be made
U01	Research Project Cooperative Agreement discrete, specified, circumscribed project to be performed by the named investigator(s) in an area representing his/her specific interest and competencies
U19	Research Program Cooperative Agreements support research programs that have multiple projects directed towards specific major objective, basic theme, or program goal, requiring a broad-based, multidisciplinary, and often long-term, approach.
R03	Small Grants research support specifically limited in time and amount for studies in categorical program areas. Small grants provide flexibility for initiating studies, which are generally for preliminary short-term projects and are non-renewable.
R21	Exploratory/Developmental Grants Phase I development of new research activities in categorical program areas. Support generally is restricted in level of support and in time.
R33	Exploratory/Developmental Grants Phase II development of new research activities in categorical program areas. Support generally is restricted in level of support and in time.
R15	Academic Research Enhancement Award (AREA) to domestic health professional schools and other institutions offering baccalaureate or advanced degrees in health sciences, except those that have received NIH research grants and/or cooperative agreements. Supports feasibility studies and other small-scale research projects.
R55	Shannon Awards limited support to scientists whose research applications fall short of the cutoff for funding yet are at the "margin of excellence" whereby the perceived quality of the grant is statistically indistinguishable from grants that are funded.
R56	High-Priority, Short-Term Project Award provide limited interim support to enable an applicant to gather additional data for revision of a new or competing renewal application.
R41	Small Business Technology Transfer (STTR) Grants - Phase I establish the technical merit and feasibility of R&D ideas which may ultimately lead to a commercial product(s) or service(s).
R42	Small Business Technology Transfer (STTR) Grants - Phase II establish the technical merit and feasibility of R&D ideas which may ultimately lead to a commercial product(s) or service(s).
R43	Small Business Innovation Research (SBIR) Grants - Phase I projects limited in time and amount, to establish the technical merit and feasibility of R&D ideas which may ultimately lead to a commercial product(s) or service(s).
R44	Small Business Innovation Research (SBIR) Grants - Phase II in-depth development of R&D ideas whose feasibility has been established in Phase I and which are likely to result in commercial products or services.
U43	Small Business Innovation Research (SBIR) Cooperative Agreement - Phase I utilized when an assistance relationship will exist between the institute and a recipient and in which substantial programmatic involvement is anticipated between the institute and the recipient during performance of the contemplated activity.
U44	Small Business Innovation Research (SBIR) Cooperative Agreement - Phase II in-depth development of R&D ideas whose feasibility has been established in Phase I and which are likely to result in commercial products or services.

Cancer Centers by State (P30 Core Grants), Fiscal Year 2005

(Dollars in Thousands)

State	Grantee Institution	Type	Amount
Alabama	University of Alabama at Birmingham	Comprehensive	\$5,800
Arizona	University of Arizona	Comprehensive	4,096
California	Burnham Institute	Lab/Basic	3,397
	Beckman Research Institute of City of Hope	Comprehensive	2,418
	Salk Institute for Biological Sciences	Lab/Basic	2,872
	University of California Davis	Clinical	3,028
	University of California Irvine	Comprehensive	2,579
	University of California Los Angeles	Comprehensive	4,523
	University of California San Diego	Comprehensive	6,558
	University of California San Francisco	Comprehensive	7,121
	University of Southern California	Comprehensive	6,105
Colorado	University of Colorado Health Sciences Center	Comprehensive	3,563
Connecticut	Yale University	Comprehensive	82
District of Columbia	Georgetown University	Comprehensive	3,128
Florida	H. Lee Moffitt Cancer Center and Research Institute	Comprehensive	2,349
Hawaii	University of Hawaii at Manoa	Clinical	1,500
Illinois	Northwestern University	Comprehensive	4,661
	University of Chicago	Clinical	3,834
Indiana	Indiana University - Purdue University at Indianapolis	Clinical	1,468
	Purdue University West Lafayette	Lab/Basic	1,261
Iowa	University of Iowa	Comprehensive	2,447
Maine	Jackson Laboratory	Lab/Basic	2,697
Maryland	Johns Hopkins University	Comprehensive	6,551
Massachusetts	Dana-Farber Cancer Institute	Comprehensive	4,525
	Massachusetts Institute of Technology	Lab/Basic	2,900
Michigan	University of Michigan at Ann Arbor	Comprehensive	5,162
	Wayne State University	Comprehensive	2,750
Minnesota	Mayo Clinic Rochester	Comprehensive	4,971
	University of Minnesota Twin Cities	Comprehensive	3,531
Missouri	Washington University	Clinical	4,332
Nebraska	University of Nebraska Medical Center	Clinical	1,450
New Hampshire	Dartmouth College	Comprehensive	2,919
New Jersey	Robert Wood Johnson Medical School	Comprehensive	3,250
New Mexico	University of New Mexico Albuquerque	Clinical	1,382
New York	Cold Spring Harbor Laboratory	Lab/Basic	4,250
	Columbia University Health Sciences	Comprehensive	1,842
	Institute for Cancer Prevention*	Clinical	569
	New York University School of Medicine	Clinical	2,575
	Roswell Park Cancer Institute Corp	Comprehensive	3,795
	Sloan-Kettering Institute for Cancer Research	Comprehensive	10,130
North Carolina	Yeshiva University	Clinical	3,888
	Duke University	Comprehensive	6,717
	University of North Carolina Chapel Hill	Comprehensive	6,662
	Wake Forest University Health Sciences	Comprehensive	1,322
Ohio	Case Western Reserve University	Comprehensive	4,438
	Ohio State University	Comprehensive	4,033
Oregon	Oregon Health & Science University	Clinical	1,169
Pennsylvania	Fox Chase Cancer Center	Comprehensive	8,152
	Thomas Jefferson University	Clinical	4,489
	University of Pennsylvania	Comprehensive	7,565
	University of Pittsburgh at Pittsburgh	Comprehensive	5,242
	Wistar Institute	Lab/Basic	2,658
Tennessee	St. Jude Children's Research Hospital	Clinical	4,975
	Vanderbilt University	Comprehensive	5,072
Texas	University of Texas San Antonio Health Science Center	Clinical	3,069
	University of Texas M.D. Anderson Cancer Center	Comprehensive	9,301
Utah	Huntsman Cancer Institute/University of Utah	Clinical	780
Vermont	University of Vermont & St. Agric College	Comprehensive	1,348
Virginia	University of Virginia Charlottesville	Clinical	1,983
	Virginia Commonwealth University/Massey Cancer Center	Clinical	1,857
Washington	Fred Hutchinson Cancer Research Center	Comprehensive	10,012
Wisconsin	University of Wisconsin Madison	Comprehensive	5,586
	Total P30s	61	242,689
	Total Planning Grants (P20s)		7,555
	Center for AIDs Research (CFARs)		3,753
	Other P30s & U41s		1,265
Total Cancer Centers			\$255,262

* Not included in count because institution has closed.

Specialized Programs of Research Excellence, Fiscal Year 2005

(Dollars in Thousands)

In 1992, the NCI established the Specialized Programs of Research Excellence (SPORE). This program promotes interdisciplinary research and speeds the bidirectional exchange between basic and clinical science to move basic research findings from the laboratory to applied settings involving patients and populations. The goal of the SPORE program is to bring to clinical care settings novel ideas that have the potential to reduce cancer incidence and mortality, and to improve survival, and the quality of life.


Laboratory and clinical scientists work collaboratively to plan, design and implement research programs that impact on cancer prevention, detection, diagnosis, treatment and control. To facilitate this research, each SPORE develops and maintains specialized resources that benefit all scientists working on the specific cancer site, as well as SPORE scientists. An additional SPORE element is a career development program that recruits scientists both within and outside the SPORE institution to enlarge the cadre of laboratory and clinical scientists dedicated to translational research on human cancer. SPOREs meet annually to share data, assess research progress, identify new research opportunities and establish research priorities.

Mechanism	Site	No.	Amount
P50 SPOREs	Brain	4	\$6,938
	Breast	10	21,304
	Cervical	1	2,456
	Genitourinary	2	5,329
	Gastrointestinal	4	10,175
	Head and Neck	4	7,065
	Leukemia	1	2,492
	Lung	6	14,583
	Lymphoma	3	7,178
	Myeloma	1	2,253
	Ovarian	5	10,023
	Pancreatic	1	2,299
	Prostate	11	29,003
	Skin	3	6,580
	Uterine	1	1,949
	Total P50s	57	129,627
P20 SPOREs	Lung	1	1,057
	Pancreatic	2	1,956
	Total P20s	3	3,013
	Subtotal	60	132,640
Co-funded	Urology with NIDDK		385
Total		60	\$133,025

NRSA Predoctoral and Postdoctoral Trainees


Fiscal Years 1994 - 2005

(Full Time Trainee Positions)



Construction/Renovation Funding Fiscal Years 1994 - 2005

(Dollars in Thousands)



*Excludes Buildings and Facilities used for repairs and improvements at the NCI - Frederick facility totalling \$7,936 in FY 2005.

Grant and Contract Awards by State Fiscal Year 2005

(Dollars in Thousands)

State	Grants		Contracts		Total NCI		State
	No	Amount	No	Amount	No	Amount	
Alabama	81	\$39,755	9	\$7,823	90	\$47,578	Alabama
Alaska	4	2,309	0	0	4	2,309	Alaska
Arizona	92	51,418	3	1,984	95	53,402	Arizona
Arkansas	17	7,577	0	0	17	7,577	Arkansas
California	933	488,527	27	118,816	960	607,343	California
Colorado	110	33,756	3	3,671	113	37,427	Colorado
Connecticut	93	27,576	2	2,992	95	30,568	Connecticut
Delaware	3	1,494	0	0	3	1,494	Delaware
District of Columbia	84	30,764	23	9,414	107	40,178	District of Columbia
Florida	163	48,706	3	4,539	166	53,246	Florida
Georgia	77	28,088	7	4,657	84	32,744	Georgia
Hawaii	21	12,732	3	4,652	24	17,384	Hawaii
Idaho	2	383	0	0	2	383	Idaho
Illinois	227	99,426	20	10,696	247	110,122	Illinois
Indiana	59	20,169	1	100	60	20,269	Indiana
Iowa	36	16,182	4	4,707	40	20,889	Iowa
Kansas	19	6,304	5	3,871	24	10,175	Kansas
Kentucky	56	15,570	4	2,129	60	17,698	Kentucky
Louisiana	48	13,003	1	1,725	49	14,728	Louisiana
Maine	7	4,494	0	0	7	4,494	Maine
Maryland	246	129,863	74	106,653	320	236,516	Maryland
Massachusetts	642	310,916	9	4,799	651	315,715	Massachusetts
Michigan	222	98,412	7	13,444	229	111,856	Michigan
Minnesota	170	85,672	5	8,337	175	94,009	Minnesota
Mississippi	3	471	0	0	3	471	Mississippi
Missouri	127	58,495	9	8,341	136	66,836	Missouri
Montana	5	1,719	0	0	5	1,719	Montana
Nebraska	32	12,850	1	1	33	12,851	Nebraska
Nevada	7	2,245	0	0	7	2,245	Nevada
New Hampshire	54	24,520	2	352	56	24,873	New Hampshire
New Jersey	88	32,166	4	3,910	92	36,077	New Jersey
New Mexico	33	13,358	1	1,993	34	15,352	New Mexico
New York	659	285,459	11	9,134	670	294,594	New York
North Carolina	294	131,973	10	3,847	304	135,819	North Carolina
North Dakota	7	1,528	0	0	7	1,528	North Dakota
Ohio	294	104,901	10	5,990	304	110,891	Ohio
Oklahoma	16	4,271	2	1,485	18	5,755	Oklahoma
Oregon	62	20,434	0	0	62	20,434	Oregon
Pennsylvania	563	297,920	9	5,300	572	303,220	Pennsylvania
Rhode Island	49	15,505	0	0	49	15,505	Rhode Island
South Carolina	56	15,458	0	0	56	15,458	South Carolina
South Dakota	4	3,695	0	0	4	3,695	South Dakota
Tennessee	189	89,445	1	2,609	190	92,054	Tennessee
Texas	491	226,800	14	5,542	505	232,342	Texas
Utah	36	16,134	2	2,375	38	18,509	Utah
Vermont	17	6,693	0	0	17	6,693	Vermont
Virginia	114	37,838	12	57,146	126	94,984	Virginia
Washington	261	144,568	8	7,907	269	152,475	Washington
West Virginia	6	1,074	2	862	8	1,936	West Virginia
Wisconsin	108	43,395	4	2,956	112	46,351	Wisconsin
Subtotal	6,987	3,166,012	312	434,759	7,299	3,600,771	Subtotal
American Samoa	1	368	0	0	1	368	American Samoa
Guam	1	495	0	0	1	495	Guam
Puerto Rico	5	2,515	0	0	5	2,515	Puerto Rico
Total	6,994	3,169,391	312	434,759	7,306	3,604,150	Total

Excludes NRSA TAP, Loan Repayment Program, Foreign Contracts and Grants, Program Evaluation, and other assessments and miscellaneous expenses.

Grant and Contract Awards by Country Fiscal Year 2005

(Dollars in Thousands)

Country	Grant		Contract		Total NCI		Country
	No	Amount	No	Amount	No	Amount	
Argentina		49				49	Argentina
Australia	14	4,749			14	4,749	Australia
Belgium	1	426			1	426	Belgium
Canada	18	9,629	2	\$632	20	10,261	Canada
China		20	2	259	2	279	China
Costa Rica			1	3,450	1	3,450	Costa Rica
Denmark			1	43	1	43	Denmark
Finland			1	746	1	746	Finland
France	6	2,064			6	2,064	France
Germany	2	97			2	97	Germany
India	1	201			1	201	India
Israel	11	1,696			11	1,696	Israel
Italy			1	200	1	200	Italy
Netherlands	1	183			1	183	Netherlands
Russia			2	191	2	191	Russia
Senegal	1	27			1	27	Senegal
South Africa	2	167			2	167	South Africa
Spain	1	194			1	194	Spain
Sweden	5	1,622	1	105	6	1,727	Sweden
Switzerland	2	291			2	291	Switzerland
United Kingdom	3	279			3	279	United Kingdom
West Indies			1	570	1	570	West Indies
Total Foreign	68	21,694	12	6,196	80	27,890	

Institutions Receiving More than \$15 Million in NCI Support, FY 2005

(Dollars in Thousands)

State	Institution	Grants	Contracts	Total NCI
Alabama	University of Alabama at Birmingham	\$34,459	\$4,122	\$38,581
Arizona	University of Arizona	37,818	1,747	39,565
California	Beckman Research Inst of City of Hope	18,498		18,498
	Burnham Institute	23,395	725	24,120
	National Childhood Cancer Foundation	39,438		39,438
	Science Applications International Corporation		94,072	94,072
	Scripps Research Institute	21,999		21,999
	Stanford University	38,929		38,929
	University of California System	180,697	4,234	184,931
	University of Southern California	46,703	3,486	50,189
Colorado	University of Colorado Health Sciences Center	20,855	2,889	23,744
Connecticut	Yale University	22,203	934	23,137
District of Columbia	Georgetown University	22,448	2,175	24,623
Florida	H. Lee Moffitt Cancer Ctr. & Research Institute	20,954		20,954
Georgia	Emory University	18,181	1,208	19,389
Illinois	Northwestern University	27,194	2,079	29,273
	University of Chicago	37,096	1,134	38,230
	University of Illinois at Chicago	15,252	1,929	17,181
Iowa	Iowa University	14,708	4,707	19,414
Maryland	Johns Hopkins University	84,585	717	85,302
	Westat Inc.		34,490	34,490
Massachusetts	Beth Israel Deaconess Medical Center	21,310		21,310
	Brigham & Women's Hospital	37,416		37,416
	Dana-Farber Cancer Institute	68,474		68,474
	Harvard University	36,074		36,074
	Massachusetts General Hospital	34,787		34,787
	Massachusetts Institute of Technology	22,345		22,345
Michigan	University of Michigan at Ann Arbor	63,732	3,515	67,247
	Wayne State University	16,309	5,263	21,571
Minnesota	Mayo Clinic Rochester	52,312	3,413	55,725
	University of Minnesota Twin Cities	29,759	4,924	34,683
Missouri	Washington University	44,380	6,390	50,770
New Hampshire	Dartmouth College	23,974	254	24,228
New York	Columbia University Health Sciences	27,754		27,754
	Mount Sinai School of Medicine	15,822		15,822
	New York University School of Medicine	19,448		19,448
	Roswell Park Cancer Institute Corp	33,692		33,692
	Sloan-Kettering Institute for Cancer Research	65,715	1,509	67,223
	Yeshiva University	25,977		25,977
North Carolina	Duke University	61,393	658	62,051
	University of North Carolina Chapel Hill	49,615		49,615
Ohio	Case Western Reserve University	25,641		25,641
	Cleveland Clinic Lerner College	15,884		15,884
	Ohio State University	40,321	1,807	42,127
Pennsylvania	American College of Radiology	39,306		39,306
	Fox Chase Cancer Center	30,956	1,949	32,904
	NSABP Foundation, Inc.	21,277		21,277
	Thomas Jefferson University	16,355		16,355
	University of Pennsylvania	73,397	688	74,085
	University of Pittsburgh at Pittsburgh	53,107	2,019	55,126
Tennessee	St. Jude Children's Research Hospital	25,647	2,609	28,256
	Vanderbilt University	55,988		55,988
Texas	Baylor College of Medicine	36,693		36,693
	CTRC Research Foundation	18,877		18,877
	University of Texas MD Anderson Cancer Center	113,726	4,656	118,382
Utah	University of Utah	14,847	2,375	17,223
Virginia	University of Virginia Charlottesville	18,234		18,234
	Department of Interior		53,212	53,212
Washington	Fred Hutchinson Cancer Research Center	91,066	6,204	97,270
	University of Washington	32,435	1,404	33,840
Wisconsin	University of Wisconsin Madison	34,427	1,649	36,075
	Total	\$2,233,881	\$265,143	\$2,499,024

Includes Manpower Development Grants

Appropriations of the NCI 1938-2005

(In Whole Dollars)

1938 - 1969	\$1,875,699,720	
1970 - 1979	6,073,870,500	
1980 - 1989	11,958,860,000	
1990.....	1,664,000,000	<i>prior to reductions in PL 101-166 (-\$6,839,000) and PL101-239 (-\$22,829,000).</i>
1991.....	1,766,324,000	<i>prior to reductions in PL 101-517 (-\$8,972,000 for salary and expense reduction; -\$42,568,000 for across-the-board reduction).</i>
1992.....	1,989,278,000	<i>prior to reductions in PL 102-170 (-\$21,475,000 for salary and expense reduction; -\$1,262,000 for travel reduction; \$15,000,000 transferred to other institutes for cancer research).</i>
1993.....	2,007,483,000	<i>prior to reductions in PL 102-294 (-\$16,060,000 for .8% reduction to all line items, -\$9,933,000 for S&E reduction, -\$139,000 for consultant services reduction).</i>
1994.....	2,082,267,000	<i>prior to reduction in PL103-211 (-\$5,885,000 administration reduction).</i>
1995.....	2,135,119,000	<i>prior to reductions in PL 103-211 (-\$1,883,000 for Procurement reduction; -\$116,000 for SLUC reduction; -\$1,052,000 for Bonus Pay reduction). Includes \$218,199,000 of AIDS funding.</i>
1996.....	2,251,084,000	<i>Includes \$225,790,000 of AIDS funding.</i>
1997.....	2,382,532,000	<i>Includes \$224,983,000 of AIDS funding.</i>
1998.....	2,547,314,000	<i>prior to reductions in PL 105-119 (-\$4,755,000 via the Secretary's 1% transfer authority). Includes \$8,699,000 transferred via the NIH Director's 1% transfer authority, \$41,000 transfer from U.S. Dept. of State in PL 105-119, and \$226,414,000 of AIDS funding.</i>
1999.....	2,927,187,000	<i>prior to reductions in PL 106-51 (-\$1,940,000 for travel and admin. expenses). Includes -\$931,000 transferred via the Secretary 1% transfer authority, and -\$6,259,000 transferred via the NIH Director's 1% transfer authority, and \$239,190,000 of AIDS funding.</i>
1990 - 1999	21,752,588,000	
2000.....	3,332,317,000	<i>prior to reductions in PL 106-113 (-\$17,763,000 for across the board reduction). Includes \$245,804,000 of AIDS funding.</i>
2001.....	3,757,242,000	<i>prior to reductions in PL 106-554(-\$2,005,000 for across-the-board reduction). Includes -\$711,000 Secretary's 1% transfer, -\$781,000 transfer for Office of Human Research Protection and -\$24,000 lapse. Includes \$255,960,000 of AIDS funding.</i>
2002.....	4,190,405,000	<i>prior to reductions in PL 107-116(-\$4,524,000 via the Secretary's 1% transfer authority, -\$2,054,000 for the enacted rescission, -\$7,118,000 administrative reduction and -\$8,000 lapse). Includes \$254,396,000 of AIDS funding.</i>
2003.....	4,622,394,000	<i>prior to reductions in PL 108-7(-\$30,046,000 for the enacted rescission and -\$2,000 lapse). Includes \$263,442,000 of AIDS funding.</i>
2004.....	4,770,519,000	<i>prior to reductions in PL 108-199(-\$3,136,000 for Labor/HHS/ED rescission; \$28,128,000 for across the board reduction; -\$15,357,000 NIH 1% transfer assessment, and \$5,000 lapse). Includes \$266,975,000 of AIDS funding.</i>
2005.....	4,865,525,000	<i>prior to reductions in PL 108-447(\$38,914,000 .8% across the board reduction; -\$1,353,000 for Labor/HHS/ED rescission; -\$30,505,000 NIH 1% transfer assessment, and \$9,000 lapse). Includes \$265,907,000 of AIDS funding.</i>
1938-2005	67,199,420,220	


By-Pass Budget Requests Fiscal Years 1973-2007

(In Whole Dollars)

Fiscal Year	Request
1973.....	\$550,790,000
1974.....	640,031,000
1975.....	750,000,000
1976.....	898,500,000
1977.....	948,000,000
1978.....	955,000,000
1979.....	1,036,000,000
1980.....	1,055,000,000
1981.....	1,170,000,000
1982.....	1,192,000,000
1983.....	1,197,000,000
1984.....	1,074,000,000
1985.....	1,189,000,000
1986.....	1,460,000,000
1987.....	1,570,000,000
1988.....	1,700,000,000
1989.....	2,080,000,000
1990.....	2,195,000,000
1991.....	2,410,000,000
1992.....	2,612,000,000
1993.....	2,775,000,000
1994.....	3,200,000,000
1995.....	3,600,000,000
1996.....	3,640,000,000
1997.....	2,977,000,000
1998.....	2,702,500,000
1999.....	3,191,000,000
2000.....	3,873,000,000
2001.....	4,135,000,000
2002.....	5,030,000,000
2003.....	5,690,000,000
2004.....	5,986,000,000
2005.....	6,211,000,000
2006.....	6,170,000,000
2007.....	5,949,714,000

The National Cancer Act in December 1971, included a provision for the Director, NCI to submit an annual budget request directly to the President, with comment only by NIH and DHHS. This Bypass Budget was first submitted for 1973.

Bypass Requests and Appropriations of the NCI Fiscal Years 1974-2007





Comparison of Dollars, Positions and Space Fiscal Years 1994-2005

Funds are obligations against the annual appropriation in millions of dollars

FTEs are the number of workyears for appointed employees of the NCI. A workyear equals 2,080 hours.

The increase in FTEs in FY 2000 is due to the fact that 195 contract staff were converted to NCI appointments.

Space is in thousands of square feet, excluding NCI-Frederick.



Personnel Resources Fiscal Years 1996-2005

Fiscal Year	Full Time Appointment	Part Time Appointment	Training Fellows	Total Personnel Resources
1996	1,841	460	960	3,261
1997	1,915	422	1,023	3,360
1998	1,921	466	1,124	3,511
1999	1,941	628	1,060	3,629
2000	2,139	831	1,202	4,172
2001	2,224	912	963	4,099
2002	2,250	979	949	4,178
2003	2,193	1,073	1,191	4,457
2004	2,083	990	1,232	4,305
2005	1,959	882	1,077	3,918

AIDS Funding History

Fiscal Years 1993-2005

(Dollars in Thousands)

Fiscal Year	NCI	NIH	% NCI of NIH
1993	\$173,029	\$1,073,957	16%
1994	212,868	1,298,996	16%
1995	217,430	1,333,600	16%
1996	225,360	1,411,860	16%
1997	224,733	1,501,073	15%
1998	225,991	1,559,071	14%
1999	239,190	1,797,422	13%
2000	244,145	2,005,100	12%
2001	237,789	2,244,160	11%
2002	254,396	2,500,866	10%
2003	263,442	2,718,171	10%
2004	266,975	2,840,384	9%
2005	265,907	2,909,381	9%

